WO2020152200A1 - Process for preparation of heteroarylketones - Google Patents

Process for preparation of heteroarylketones Download PDF

Info

Publication number
WO2020152200A1
WO2020152200A1 PCT/EP2020/051465 EP2020051465W WO2020152200A1 WO 2020152200 A1 WO2020152200 A1 WO 2020152200A1 EP 2020051465 W EP2020051465 W EP 2020051465W WO 2020152200 A1 WO2020152200 A1 WO 2020152200A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
formula
hydrogen
compound
aryl
Prior art date
Application number
PCT/EP2020/051465
Other languages
French (fr)
Inventor
Swapnil Yerande
Harish SHINDE
Vishal BHOR
Prashant KAPSE
Roland Goetz
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2020152200A1 publication Critical patent/WO2020152200A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to a process for the preparation of heteroarylketones of the formula (I).
  • the invention relates to an efficient process for the preparation of heteroarylketones of the formula (I) which are used as herbicides.
  • Heteroarylketones of formula (I) are described in WO96/26206 and WO98/31681.
  • the heteroarylketones of formula (I) are directed to an herbicidal compound 4-[3-(4,5-dihydro- 1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1H-pyrazol-3-one or [3-(4,5- dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]-(5-hydroxy-1-methyl-pyrazol-4- yl)methanone.
  • WO 96/26206 discloses a process for preparing 4-(3-(4,5-dihydroisoxazol-3-yl) benzoyl)-5- hydroxypyrazoles where, in the last step, a 5-hydroxypyrazole is reacted with a 3-(4,5- dihydroisoxazol-3-yl) benzoic acid derivative.
  • the 3-(4,5-dihydroisoxazol-3-yl) benzoic acid derivative required for this process can only be obtained with difficulty, via several steps. Accordingly, the process is relatively expensive and not optimal economically.
  • DE 19709118 describes a process for preparing 3-(4,5-dihydroisoxazol-3-yl) benzoic acids starting from 3-bromo-(4,5-dihydroisoxazol-3-yl) benzene, Grignard reagents and carbon dioxide.
  • WO 99/58509 describes a process for preparing 3-heterocyclyl-substituted benzoyl derivatives with reduced steps. However, the yields obtained by the process are not satisfactory.
  • a first aspect of the present invention relates to a process for the preparation of a compound of the general formula (I) or its salts as describes in step (A).
  • R1 is C 1 -C 4 alkyl
  • R 2 is Cl or C 1 -C 4 alkyl
  • 3 is hydrogen or C 1 -C 4 alkyl
  • 4 is C 1 -C 4 alkyl, comprising at least the step of reacting a compound of formula (II),
  • R1 is C 1 -C 4 alkyl and M is H or an alkali metal atom with a compound of formula
  • R 2 is Cl or C 1 -C 4 alkyl
  • R3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound.
  • Step B Further, the compound of general formula (III) is obtained by one or more of the following steps: a) reacting a nitro-methylphenyl compound of formula IV,
  • R 2 is Cl or C 1 -C 4 alkyl, with an organic nitrile of the formula R 5 -ONO, wherein R 5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
  • R 2 is Cl or C 1 -C 4 alkyl, a) cyclization of the oxime of the formula (V) with an alkene of the formula (VI),
  • R6, R7, R8 are, identical or different, hydrogen or C 1 -C 4 alkyl, in the presence of at least one base to give a compound of formula (VII),
  • R 2 is Cl or C 1 -C 4 alkyl
  • R3 is hydrogen or C 1 -C 4 alkyl
  • R4 is C 1 -C 4 alkyl
  • R 2 is Cl or C 1 -C 4 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl
  • Salts of the compounds according to the invention can be formed in a customary manner, for example, by reacting the compound with an acid of the anion in question, if the compounds according to the invention have a basic functionality or by reacting acidic compounds according to the invention with a suitable base. Salts of the compounds prepared according to the invention are preferably agriculturally acceptable salts.
  • the organic moieties or groups mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members.
  • the term "C v -C w " indicates the number of carbon atom possible in each case.
  • the term "halogen” refers to flouro, chloro, bromo and iodo.
  • the term "C 1 -C 4 -alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1,1-dimethylethyl.
  • the term“substituted” if not specified otherwise refers to substituted with 1, 2 or maximum possible number of substituents. If substituents are more than one, then they are independently from each other are same or different, if not mentioned otherwise.
  • Step (A) of the present invention for the preparation of a compound of the general formula (I) or its salts is as follows: Reacting a compound of formula (II), wherein
  • R 1 is C 1 -C 4 alkyl and M is H or an alkali metal atom with a compound of formula (III),
  • R is Cl or C 1 -C 4 alkyl
  • R is hydrogen or C 1 -C 4 alkyl
  • R4 is C 1 -C 4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound to obtain a compound of formula (I)
  • R 1 is C 1 -C 4 alkyl
  • R 2 is Cl or C 1 -C 4 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R4 is C 1 -C 4 alkyl.
  • R 1 is C ! _C 2 alkyl
  • R 2 is C 1 --C 4 alkyl
  • R 3 is hydrogen or C 1 --C 4 alkyl
  • R 4 is C1-C4 alkyl.
  • R 1 is methyl
  • R 2 is C 1 --C 2 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl.
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is C 1 -C 4 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is C 1 --C 2 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is methyl
  • R 4 is methyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is methyl
  • the temperatures and the duration times of the reactions may be varied in broad ranges, which the person skilled in the art knows from analogous reactions.
  • the temperatures often depend on the reflux temperature of the solvents or at higher temperature under pressure.
  • the end of the reaction can be monitored by methods known to a person skilled in the art, for example, thin layer chromatography or H PLC or GC.
  • the mass ratio of reactant to solvent is in the range of 1: 5 to 1: 20,
  • the mass ratio of reactant to solvent is in the range of 1:6 to 1:10.
  • reactants can in principle be contacted with one another in any desired sequence.
  • step (A) takes place in the presence of at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound and at least one solvent, wherein the at least one metal is preferably in a form of a free state of formula M or in a form of a metal complex of formula M(L) n
  • step (A) of the invention In the following, preferred embodiments regarding step (A) of the invention are provided. It is to be understood that the preferred embodiments mentioned above and those still to be illustrated below of step (A) of the invention are to be understood as preferred alone or in combination with each other.
  • the at least one alkali metal iodide is selected from the group consisting of sodium iodide, potassium iodide, lithium iodide. In a preferred embodiment, the at least one alkali metal iodide is sodium iodide. In one embodiment, the at least one metal (M) is selected from the group consisting of nickel (Ni), cobalt (Co), iron (Fe), ruthenium (Ru), rhodium (Rh), palladium (Pd), iridium (Ir), platinum (Pt), silver (Ag), copper (Cu), zinc (Zn), molybdenum (Mo) and tungsten (W).
  • the at least one metal (M) is selected from the group consisting of palladium (Pd), nickel (Ni), copper (Cu) and iron (Fe).
  • L identical or different, is Cl, Br, I, P(C 5 -C 14 -aryl) m , P(C 5 -C 12 -heteroaryl) m , P(C 5 -C 12 -heteroaryl) m (C 5 -C 14 -aryl) 3-m , CN, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-O-C 1 -C 6 -alkyl, -O-CO-C 1 - C 6 -alkyl, OH, nitro, -O-C 1 -C 6 -alkyl, C 1 -C 4 -haloalkoxy, C 3 -C 8 -cycloalkyl, C 3 -C 8 -halocycloalkyl,
  • R14 is hydrogen or C 1 -C 4 -alkyl
  • R15 is hydrogen or C 1 -C 4 -alkyl
  • R16 is hydrogen, C 1 -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 5 -C 14 -aryl, C 5 -C 12 -heteroaryl or C 3 -C 12 -cycloalkyl;
  • n 0,1,2,3,4,5 or 6
  • n 1,2 or 3;
  • o 0,1 or 2
  • p 0,1 or 2
  • L is, identical or different, Cl, Br, I, P(C 5 -C 14 -aryl) m , CN, unsubstituted or substituted C 1 -C 12 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 8 -cycloalkenyl, -O-CO-C 1 -C 6 - alkyl, C 5 -C 14 -aryl, 1,1 ⁇ - bis(diphenyl phosphino)ferrocene and C 5 -C 14 -aryl-(CH 2 ) o -(Q) p -(CH 2 ) o - C 5 -C 14 -aryl;
  • n 1,2 or 3;
  • o 0,1 or 2
  • L is, identical or different, Cl, -OCOCH 3 , P(phenyl) 3 , P(o- tolyl) 3 , CN, dibenzylidene acetone, -CH 3 CN, 1,5-cyclooctadiene or 1,1 ⁇ - bis(diphenyl phosphino) ferrocene.
  • Ln is supported on silica gel, dendrimers, polystyrenes or mesoporous siliceous foam, for example as described in Vivek et. al., Tetrahedron, 63, 2007, 6949-6976.
  • R 8 is hydrogen, C 1 -C 12 alkyl, C 5 -C 14 -aryl or C 5 -C 12 -heteroaryl.
  • R 8 is hydrogen, methyl or ethyl.
  • R 9 is hydrogen, C 1 -C 12 alkyl, C 5 -C 14 -aryl or C 5 -C 12 -heteroaryl.
  • R 9 is hydrogen
  • R 10 is hydrogen, methyl, ethyl, propyl or n-butyl.
  • R 1 1 is hydrogen, methyl, ethyl, propyl or butyl.
  • R 12 is hydrogen, methyl, ethyl, propyl or butyl.
  • R 13 is hydrogen, methyl, ethyl, propyl or butyl.
  • R 13 is hydrogen, methyl or ethyl.
  • R10 together with R11 forms C 5 -C 12 -membered heterocycloalkyl, C 5 -C 12 -membered heterocycloalkenyl or C 5 -C 12 -membered heteroaryl.
  • R 14 is hydrogen or C 1 -C 4 -alkyl.
  • R14 is hydrogen, methyl, ethyl, propyl or butyl.
  • R 15 is hydrogen, methyl, ethyl, propyl or butyl.
  • R16 is hydrogen, C 1 -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 5 -C 14 -aryl, C 5 -C 12 -heteroaryl or C 3 -C 12 -cycloalkyl.
  • n 0,1,2,3,4,5 or 6.
  • n 0,1 or 2.
  • n 3,4,5 or 6.
  • n 2, 3 or 4.
  • m is 1, 2 or 3.
  • o is 0,1 or 2
  • p is 0,1 or 2 and
  • r is 1,2,3,4 or 5.
  • M, L and n are as follows in Table 1: Table 1
  • the amount of at least one M and/or MLn is in the ratio of 1: 100 mole to 1:500 mole of the compound of formula (III).
  • the amount of at least one M and/or MLn is in the ratio of 1: 150 mole to 1:400 mole of the compound of formula (III)
  • the at least one metal catalyst is in a free state of palladium such as Pd/C.
  • the at least one metal catalyst is in a form of a metal complex selected from the group consisting of Pd(OCOCH 3 ) 2 and Pd(CI) 2 .
  • the phosphine compound is PX 1 X 2 X 3 or (PX 1 X 2 ) 2 (B) q , whereby X 1 , X 2 and X 3 , identical or different, are F, Cl, Br, I, -NR 17 R 18 hydrogen, -0-C 1 -C 6 -alkyl, -0-CO-C 1 -C 6 -alkyl, -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -al kyny I, C 5 -C 14 -aryl, C 5 -C 12 -heteroaryl, C 3 -C 12 -cycloalkyl, C 3 - C 12 -cycloalkenyl, C 3 -C 12 -heterocycloalkyl, C 3 -C 12 -heterocycloalkenyl or -Si-(C 1 --C 12 -alkyl) 3 ,
  • r is 1,2, 3, 4 or 5;
  • R 23 is hydrogen or C 4 -C 4 -a I ky I ;
  • R 24 is hydrogen or C 4 -C 4 -a I ky I ;
  • R 25 is hydrogen, C 1 --C 12 -a I ky I , C 2 -C 6 -alkenyl, C 2 -C 6 -a I kyny I , C 5 -C 14 -aryl, C 5 -C 12 -heteroaryl or C 3 - C 12 -cycloalkyl;
  • X 4 , X 2 and X 3 are C 1 --C 12 -a I kyl , C 5 -C 14 -aryl or C 5 - C 12 -heteroaryl.
  • X 4 , X 2 and X 3 are methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1- methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1- dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4- methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3- d i methyl butyl , 3,3-dimethylbutyl, 1-ethyl butyl, 2-ethyl butyl, 1,1,2-trimethyl propyl,
  • X 1 , X 2 and X 3 are phenyl or naphthyl.
  • X 1 , X 2 and X 3 identical or different, are pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiadiazolyl, oxadiazolyl, and tetrazolyl rings, and the fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C 8 -C 10 bicyclic group such as indolyl, benzimidazolyl
  • R17 is hydrogen, methyl, ethyl, propyl or butyl.
  • R18 is hydrogen, methyl, ethyl, propyl or butyl.
  • R18 is hydrogen
  • R17 together with R18 forms C 5 -C 12 -membered heterocycloalkyl, C 5 -C 14 -membered heterocycloalkenyl or C 5 -C 12 -heteroaryl.
  • R19 is hydrogen, C 1 -C 12 -alkyl, C 5 -C 14 -aryl or C 5 -C 12 -heteroaryl.
  • R19 is hydrogen, methyl ethyl, propyl, phenyl or naphthyl.
  • R20 is hydrogen, C 1 -C 12 -alkyl, C 5 -C 14 -aryl or C 5 -C 12 -heteroaryl.
  • R20 is hydrogen, methyl ethyl, propyl or butyl.
  • R21 is hydrogen or C 1 -C 4 alkyl.
  • R21 is hydrogen
  • R22 is hydrogen, methyl, ethyl, propyl or butyl.
  • R22 is hydrogen, methyl or ethyl.
  • R23 is hydrogen or C 1 -C 4 -alkyl.
  • R23 is hydrogen, methyl, ethyl, propyl or butyl.
  • R24 is hydrogen methyl, ethyl, propyl or butyl.
  • the at least one phosphine compound is selected from the group consisting of allyldiphenylphosphine; 1,3-bis(diphenylphosphino)propane; 1,3-bis(dicyclo- hexylphosphino)propane, 1,4-bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phos- phine, tri-tert-butylphosphine ,di-tert-butyl(phenyl)phosphine tetrafluoroborate; (2-am- monioethyl) di-tert-butylphosphonium bis(tetrafluoroborate); (2-ammonioethyl) diiso- propylphosphonium bis(tetrafluoroborate); (3-ammoniopropyl) di-tert
  • dicyclohexyl(4-isopropylphenyl)phosphine dicyclohexyl(2-methylphenyl)phosphine
  • dicyclohexylphenylphosphine 2 ⁇ -(dicyclohexylphosphino)acetophenone ethylene ketal; 2- (dicyclohexylphosphino)benzophenone; 2-(dicyclohexylphosphino)-N,N-diisopropyl-1H- indole-1-carboxamide; N -(dicyclohexyl phosphino)-2-(2 ⁇ -methoxyphenyl)indole; 2- [(dicyclohexylphosphino)methyl]-1,3-bis(2,6-diisopropylphenyl)-4,5-dimethylimidazolium iodide; 2-(2-dicyclohexylphosphinophenyl)-1,3-dioxolane; 2-[2- (dicyclohexylphosphino)phenyl]-N-methylindole; dicyclohexyl(2,
  • dimethylaminophenylchlorophosphine 4-(dimethylamino)phenyldiphenylphosphine; 2-(1,1- dimethylpropyl)-6-(diphenylphosphino)pyridine; diphenyl(2-methoxyphenyl)phosphine; 4- diphenylphosphanylbenzoic acid; 2-(diphenylphosphino)benzaldehyde; 2- (diphenylphosphino)benzaldehyde oxime; 3-(diphenylphosphino)benzenesulfonic acid sodium salt; 2-(diphenylphosphino)benzoic acid; 4-(diphenylphosphino)benzoic acid; N-[2- (diphenylphosphino)benzylidene] cyclohexylamine; 2-(diphenylphosphino)-N,N- dimethylbenzylamine; 2-(diphenylphosphino)ethana
  • methyldiphenylphosphine 1-methyl-2-(2-diphenylphosphinophenyl)-1H-benzoimidazole; 1,2,3,4,5-pentaphenyl-1 ⁇ -(di-tert-butylphosphino)ferrocene; phenylbis[4- (3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)phenyl]phosphine; phenyldi(o-tolyl)phosphine; phenylphosphine; 4,4 ⁇ -(phenylphosphinidene)bis(benzenesulfonic acid) dipotassium salt hydrate; tetrapropylphosphonium bromide; triallylphosphine; tribenzylphosphine;
  • tributylphosphine tri-n-butylphosphine; tri-tert-butylphosphine; tri-tert-butylphosphine; tri- tert-butylphosphine; tributylphosphine tetrafluoroborate; tri-tert-butylphosphonium tetrafluoroborate; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine tetrafluoroborate; tricyclopentylphosphine; tricyclopentylphosphine tetrafluoroborate; triethylphosphine; triethylphosphine; ((4-trifluoromethyl)phenyl)di-tert- butylphosphine, tri(2-furyl)phosphine; ((2,4,6-tri-is
  • triphenylphosphine triphenylphosphine; triphenylphosphine hydrobromide; 4-(triphenylphosphonio)butane-1- sulfonate; tripropylphosphine; tris[3,5-bis(trifluoromethyl)phenyl]phosphine; tris(4- chlorophenyl)phosphine; tris(diethylamino)phosphine; tris(2,6-dimethoxyphenyl)phosphine; tris(dimethylamino)phosphine; tris(3,5-dimethylphenyl)phosphine; tris(2,4-dimethyl-5- sulfanatophenyl)phosphine trisodium salt; tris[2-(diphenylphosphino)ethyl]phosphine;
  • tris(hydroxymethyl)phosphine tris(4-methoxy-3,5-dimethylphenyl)phosphine; tris(o- methoxyphenyl)phosphine; tris(4-methoxyphenyl)phosphine; tris(4-methyl-1- piperazinyl)phosphine; tris(pentafluorophenyl)phosphine; tris(1-pyrrolidinyl)phosphine; tris[4-(tridecafluorohexyl)phenyl]phosphine; tris[4-(3,3,4,4,5,5,6,6,7,7,8,8,8- tridecafluorooctyl)phenyl]phosphine; tris(4-trifluoromethylphenyl)phosphine; tris(2,4,6- trimethoxyphenyl)phosphine; tris(2,4,6-trimethylphenyl)phosphine;
  • tris(trimethylsilyl)phosphine tri(o-tolyl)phosphine; tri(p-tolyl)phosphine; tri-o- tolylphosphine tetrafluoroborate; and 2-(dicyclohexylphosphino)-3,6-dimethoxy- 2 ⁇ ,4 ⁇ ,6 ⁇ -triisopropyl-1,1 ⁇ -biphenyl or acceptable salts thereof.
  • the at least one phosphine compound is selected from the group consisting of triphenylphosphine, 1,3-bis(dicyclohexylphosphino)propane, 1,4- bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phosphine and tri-tert-butylphosphine.
  • the mole ratio of at least one phosphine compound to the at least one metal catalyst is in the range of 1:0.010 to 1:0.20
  • the mole ratio of at least one phosphine compound to the at least one metal catalyst is in the range of 1:0.025 to1:0.175.
  • the mole ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.05 to1:0.160 In a most preferred embodiment, the mole ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.075 to 1:0.15.
  • reaction temperature of the step (A) is kept within a range of from 50oC to 150°C, preferably in the range of from 50°C to 130°C, more preferably in the range of from 55°C to 120°C.
  • the reaction of the step (A) is carried out at of pressure of 5 bar to 20 bar, preferably in the range of from 7 bar to 15 bar, more preferably in the range of 9 bar to 15 bar.
  • the at least one solvent of step (A) is selected from the group consisting of esters, ethers, aromatic hydrocarbons and acetals.
  • the solvent of step (A) is triethylorthoformate, trimethylorthoformate, tripropylorthoformate, tributylorthoformate, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4- dioxane, diethyl ether, diisopropyl ether, di-n-propyl ether, di-n-butyl ether, methyl-tert-butyl ether, diisobutyl ether, tetrahydropyran, dimethoxymethane, dimethoxypropane, dimethoxybutane, toluene, xylene, cyclohexane and monochlorobenzene.
  • the at least one base in step (A) is selected from organic bases or inorganic bases.
  • the organic bases are selected from the group consisting of N(R27) 3 , N- methyl piperidine, N-methyl pyrrolidine, N-methyl morpholine, piperidine, dimethyl amino pyridine, pyridine, lithium hexamethyldisilazide, sodium hexamethyldisilazide and tetra-C 1 - C 6 -alkyl ammonium hydroxide, wherein R27 is, identical or different, hydrogen, C 1 -C 6 -alkyl, C 5 - C 14 -aryl, or C 3 -C 6 -cycloalkyl.
  • the inorganic bases are selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide.
  • the alkali metal hydroxide is selected from group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide and cesium hydroxide;
  • the alkaline earth hydroxide is selected from the group consisting of magnesium hydroxide, calcium hydroxide, strontium hydroxide and barium hydroxide;
  • the alkali metal bicarbonate is selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, rubidium bicarbonate and cesium bicarbonate;
  • the alkaline earth bicarbonate is selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, strontium bicarbonate and barium bicarbonate;
  • the alkali metal carbonate is selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, rubidium carbonate and cesium carbonate;
  • the alkaline earth carbonate is selected from group the consisting of magnesium carbonate, calcium carbonate, strontium carbonate and barium carbonate;
  • the at least one inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate.
  • the at least one base is selected from the group consisting of potassium carbonate, 4-dimethylaminopyridine and triethylamine.
  • R 2 is Cl or C 1 -C 4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
  • R 2 is Cl or C 1 -C 4 alkyl and R3 is hydrogen or C 1 -C 4 alkyl, c) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VIII),
  • R 2 is Cl or C 1 -C 4 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl
  • R 2 is Cl or Ci-C 4 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl
  • R 2 is Cl or Ci-C 4 alkyl
  • R 3 is hydrogen or Cl- C4 alkyl
  • R 4 is Ci-C 4 alkyl
  • R 1 is C 1 _C 2 alkyl
  • R 2 is C 1 -C 4 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl.
  • R 1 is methyl
  • R 2 is C 1 -C 2 alkyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 - C 4 alkyl.
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen or C 1 -C 4 alkyl
  • R 4 is C 1 -C 4 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is C 1 -C 4 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is C 1 -C 2 alkyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is methyl
  • R 4 is methyl
  • R 1 is methyl
  • R 2 is methyl
  • R 3 is hydrogen
  • R 4 is methyl
  • R 6 , R 7 , R 8 are, identical or different, hydrogen or C 1 C 4 alkyl
  • R 6 , R 7 , R 8 are, identical or different, hydrogen or C 1 -C 2 alkyl
  • X is Cl, Br, l,-CF 3 .
  • X is Cl, Br.
  • X is Br
  • step (B) takes place in the presence of at least one base, at least one metal catalyst and at least one solvent.
  • the at least one base used in step (B) is selected from the group of tertiary amines, for example triethylamine, cyclic amines, such as N-methylpiperidine or N,N'- dimethylpiperazine, pyridine, alkali metal carbonates, for example sodium carbonate or potassium carbonate, alkali metal bicarbonates, for example sodium bicarbonate or potassium bicarbonate, alkaline earth metal carbonates, for example calcium carbonate, and alkali metal hydroxides, for example sodium hydroxide or potassium hydroxide.
  • tertiary amines for example triethylamine
  • cyclic amines such as N-methylpiperidine or N,N'- dimethylpiperazine
  • pyridine alkali metal carbonates
  • alkali metal bicarbonates for example sodium bicarbonate or potassium bicarbonate
  • alkaline earth metal carbonates for example calcium carbonate
  • alkali metal hydroxides for example sodium hydroxide or potassium hydroxide.
  • the at least one metal catalyst in step (B) is Ni, Pt/C, Pd/C, copper powder, elemental copper in a different form, such as, for example, turnings, wire, granules, pellets, rods; copper(l) salts, for example copper(l) chloride, copper(l) bromide or copper(l) iodide, copper(ll) salts, or elemental iodine.
  • the at least one solvent in step (B) is a haloalkane, such as 1,2- dichloroethane or methylene chloride; aromatic compounds, such as benzene, toluene, chlorobenzene, nitrobenzene or xylene; polar aprotic solvents, for example N,N- dialkylformamides, N,N-dialkylacetamides, N-methylpyrrolidone, dimethylpropyleneurea; tetramethylurea, acetonitrile, propionitrile; alcohols, such as methanol, ethanol, n-propanol or isopropanol; carboxylic acids, such as acetic acid or propionic acid; carboxylic esters, such as ethyl acetate.
  • a haloalkane such as 1,2- dichloroethane or methylene chloride
  • aromatic compounds such as benzene, toluene, chlorobenzene, nitrobenzen
  • R 1 is C 1 -C 4 alkyl
  • R 2 is Cl or C 3
  • R is hydrogen or C 1 -C 4 alkyl and R 4 is C 1 -C 4 alkyl, comprising at least the step of reacting a compound of formula (II),
  • R 1 is C 1 -C 4 alkyl and M is H or an alkali metal atom with a compound of formula (III),
  • R 2 is Cl or C 1 -C 4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
  • R 2 is Cl or C 1 -C 4 alkyl, b) cyclization of the oxime of the formula (V) with an alkene of the formula (VI),
  • R 6 , R 7 , R 8 are, identical or different, hydrogen or C 1 -C 4 alkyl, in the presence of at least one base to give a compound of formula (VII),
  • R 2 is Cl or C 1 -C 4 alkyl and R 3 is hydrogen or C 1 -C 4 alkyl, c) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VI II),
  • R 2 is Cl or C 1 -C 4 alkyl
  • R 3 is hydrogen or Ci-C 4 alkyl
  • R 2 is Cl or C 3
  • R is hydrogen or C 1 -C 4 alkyl
  • R4 is C 1 -C 4 alkyl
  • R is Cl or C 1 -C 4 alkyl
  • R is hydrogen or C1- C4 alkyl
  • R4 is C 1 -C 4 alkyl
  • M is selected from the group consisting of nickel (Ni), cobalt (Co), iron (Fe), 5 ruthenium (Ru), rhodium (Rh), palladium (Pd), iridium (Ir), platinum (Pt), silver (Ag), copper (Cu), zinc (Zn), molybdenum (Mo) and tungsten (W);
  • L is, identical or different, selected from the group consisting of Cl, Br, I, P(C 5 -C 14 - aryl) m , P(C 5 -C 12 -heteroaryl) m , P(C 5 -C 12 -heteroaryl) m (C 5 -C 14 -aryl) 3-m , CN, C 1 -C 6 -alkyl, C 1 - C 6 -alkyl-O-C 1 -C 6 -alkyl, -O-CO-C 1 -C 6 -alkyl, OH, nitro, -O-C 1 -C 6 -alkyl, C 1 -C 4 -haloalkoxy,10 C 3 -C 8 -cycloalkyl, C 3 -C 8 -halocycloalkyl, C 3 -C 8 -cycloalkenyl, C 5 -C 14 -aryl, C 5 -C 14 -aryl
  • L is supported on silica gel, dendrimers, polystyrenes or mesoporous siliceous foam,
  • R15 is hydrogen or C 1 -C 4 -alkyl
  • R16 is hydrogen or C 1 -C 4 -alkyl
  • R17 is hydrogen, C 1 -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 5 -C 14 -aryl, C 5 -C 12 -heteroaryl or C 3 -C 12 -cycloalkyl;
  • n 0, 1, 2, 3, 4, 5 or 6;
  • n 1,2 or 3;
  • o 0,1 or 2
  • p 0,1 or 2
  • r 1,2,3,4 or 5
  • M is selected from the group consisting of nickel (Ni), iron (Fe), palladium (Pd) and copper (Cu).
  • L is, identical or different, selected from the group consisting of Cl, Br, I, P(C 5 -C 14 -aryl) m , CN, unsubstituted or substituted C 1 -C 12 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 8 -cycloalkenyl, -O-CO-C 1 -C 6 -alkyl, C 5 -C 14 -aryl, 1,1 ⁇ - bis(diphenyl phosphino)ferrocene and C 5 -C 14 -aryl-(CH 2 ) o -(Q) p -(CH 2 ) o -C 5 -C 14 -aryl, whereby m, o, Q and p
  • metal complex of formula M(L)n is selected from the group consisting of Pd(OCOCH 3 ) 2 , PdCl 2 , PdCl 2 (CH 3 CN) 2 , Pd (1,1 ⁇ - bis(diphenyl phosphino)ferrocene)Cl 2 , Pd 2 (dibenzylideneacetone) 3 and
  • R18, R19, R 2 0 and R 2 are hydrogen or C 1 - C 4 -alkyl or R18 together with R19 forms C5-C12-membered heterocycloalkyl, C 5 -C 14 - membered heterocycloalkenyl or C 5 -C 12 -heteroaryl; whereby X 1 , X 2 and X 3 , identical or different, are unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -NO 2 ; -NR18R19, -P(phenyl) 2 , -OH, unsubstituted or substituted C 1 -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, unsubstituted or substituted C 5 -C 14 -ary
  • -C N-R 2 6, -SO 3 H, -O-C 1 -C 6 -alkyl and -O-Si-C 1 -C 4 -alkyl, C 5 -C 12 - membered heterocycloalkyl, C 5 -C 14 -membered heterocycloalkenyl and C 5 -C 12 - heteroaryl;
  • q is 1, 2, 3, 4, 5 or 6;
  • r is 1, 2 ,3, 4 or 5;
  • R 2 4 is hydrogen or C 1 -C 4 -alkyl
  • R 2 5 is hydrogen or C 1 -C 4 -alkyl
  • R 2 6 is hydrogen, C 1 -C 12 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 5 -C 14 -aryl, C 5 -C 12 heteroaryl or C 3 -C 12 -cycloalkyl;
  • compound is selected from the group consisting of allyldiphenylphosphine; 1,3- bis(diphenylphosphino)propane; 1,3-bis(dicyclohexylphosphino)propane, 1,4- bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phosphine , tri-tert- butylphosphine ,di-tert-butyl(phenyl)phosphine tetrafluoroborate; (2-ammonioethyl) di-tert-butylphosphonium bis(tetrafluoroborate); (2-ammonioethyl)
  • dicyclohexyl-(2,6-diisopropylphenyl)phosphine dicyclohexyl(4-(N,N- dimethylamino)phenyl)phosphine; dicyclohexyl(ethyl)phosphine; dicyclohexyl(4- isopropylphenyl)phosphine; dicyclohexyl(2-methylphenyl)phosphine;
  • dicyclohexylphenylphosphine 2 ⁇ -(dicyclohexylphosphino)acetophenone ethylene ketal; 2-(dicyclohexylphosphino)benzophenone; 2-(dicyclohexylphosphino)-N,N- diisopropyl-1H-indole-1-carboxamide; N -(dicyclohexyl phosphino)-2-(2 ⁇ - methoxyphenyl)indole; 2-[(dicyclohexylphosphino)methyl]-1,3-bis(2,6- diisopropylphenyl)-4,5-dimethylimidazolium iodide; 2-(2- dicyclohexylphosphinophenyl)-1,3-dioxolane; 2-[2-(dicyclohexylphosphino)phenyl]-N- methylindole; dicyclohexyl(2,4,
  • dimethylaminophenylchlorophosphine 4-(dimethylamino)phenyldiphenylphosphine; 2- (1,1-dimethylpropyl)-6-(diphenylphosphino)pyridine; diphenyl(2- methoxyphenyl)phosphine; 4-diphenylphosphanylbenzoic acid; 2- (diphenylphosphino)benzaldehyde; 2-(diphenylphosphino)benzaldehyde oxime; 3- (diphenylphosphino)benzenesulfonic acid sodium salt; 2-(diphenylphosphino)benzoic acid; 4-(diphenylphosphino)benzoic acid; N-[2-(diphenylphosphino)benzylidene] cyclohexylamine; 2-(diphenylphosphino)-N,N-dimethylbenzylamine; 2- (diphenylphosphino)e
  • tributylphosphine tri-n-butylphosphine; tri-tert-butylphosphine; tri-tert- butylphosphine; tri-tert-butylphosphine; tributylphosphine tetrafluoroborate; tri-tert- butylphosphonium tetrafluoroborate; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine tetrafluoroborate;
  • tricyclopentylphosphine tricyclopentylphosphine tetrafluoroborate
  • triethylphosphine triethylphosphine
  • ((4-trifluoromethyl)phenyl)di-tert-butylphosphine tri(2- furyl)phosphine
  • ((2,4,6-tri-isopropyl)phenyl)di-cyclohexylphosphine
  • triisopropylphosphine triisopropylphosphonium tetrafluoroborate; trimethylphosphine; trimethylphosphonium tetrafluoroborate; tri-1-naphthylphosphine; trioctylphosphine; triphenylphosphine; triphenylphosphine hydrobromide; 4- (triphenylphosphonio)butane-1-sulfonate; tripropylphosphine; tris[3,5- bis(trifluoromethyl)phenyl]phosphine; tris(4-chlorophenyl)phosphine;
  • tris(dimethylamino)phosphine tris(3,5-dimethylphenyl)phosphine; tris(2,4-dimethyl-5- sulfanatophenyl)phosphine trisodium salt; tris[2-(diphenylphosphino)ethyl]phosphine; tris(4-fluorophenyl)phosphine; tris[4-(heptadecafluorooctyl)phenyl]phosphine;
  • the at least one phosphine compound is selected from the group consisting of triphenylphosphine, 1,3- bis(dicyclohexylphosphino)propane, 1,4-bis(diphenylphosphino)butane, di-tert- butyl(phenyl)phosphine and tri-tert-butylphosphine.
  • the at least one base is selected from the group consisting of organic bases and inorganic bases. 14.
  • the organic bases are selected from the group consisting of N(R 2 7) 3 , N-methyl piperidine, N-methyl pyrrolidine, N-methyl morpholine, piperidine, dimethyl amino pyridine, pyridine, lithium hexamethyldisilazide, sodium hexamethyldisilazide and tetra-C 1 -C 6 -alkyl ammonium hydroxide, wherein R 2 7 is, identical or different, hydrogen, C 1 -C 6 -alkyl, C 5 -C 14 -aryl, or C 3 -C 6 -cycloalkyl. 15.
  • the inorganic bases are selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide. 16.
  • alkali metal hydroxide is selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide.
  • lithium hydroxide sodium hydroxide, potassium hydroxide, rubidium hydroxide and cesium hydroxide
  • alkaline earth hydroxide is selected from the group consisting of magnesium hydroxide, calcium hydroxide, strontium hydroxide and barium hydroxide; wherein the alkali metal bicarbonate is selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, rubidium bicarbonate and cesium bicarbonate;
  • alkaline earth bicarbonate is selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, strontium bicarbonate and barium bicarbonate;
  • alkali metal carbonate is selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, rubidium carbonate and cesium carbonate;
  • alkaline earth carbonate is selected from group the consisting of magnesium carbonate, calcium carbonate, strontium carbonate and barium carbonate; wherein the alkali metal phosphate is selected from the group consisting of
  • alkali metal alkoxide is selected from the group consisting of NaOR 2 8, KOR 2 8, RbOR 2 8 and CsOR 2 8; wherein the alkaline earth alkoxide is selected from the group consisting of Mg(OR 2 8) 2 , Ca(OR 2 8) 2 and Ba(OR 2 8) 2 ; wherein R 2 8 is, identical or different, C 1 -C 4 -alkyl. 17.
  • the at least one inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate.
  • the at least one base is selected from the group consisting of potassium carbonate, 4-dimethylaminopyridine and triethylamine.
  • the process is performed in the presence of at least one solvent which is selected from the group consisting of esters, ethers, aromatic hydrocarbons and acetals. 20.
  • esters are selected from the group consisting of triethylorthoformate, trimethylorthoformate, tripropylorthoformate and tributylorthoformate.
  • the ethers are selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, diethyl ether, diisopropyl ether, di-n-propyl ether, di-n-butyl ether, methyl-tert-butyl ether, diisobutyl ether and tetrahydropyran. 22.
  • step d) heating the reaction mixture of step c) to 60oC and adjusting the pH to1.5 using 35% hydrochloric acid
  • a round bottom flask (RBF) was charged with 22 gm (0.069 moles) of 3-(3-bromo-2-methyl- 6-methylsulfonyl-phenyl)-4,5-dihydroisoxazole followed by 100 gm of 1,4-dioxane and stirred it for 15 min. 17.6 gm (0.127 moles) of potassium carbonate was then charged in the round bottom flask. The reaction mixture was refluxed, and 50 gm of solvent was distilled off atmospherically.
  • the slurry formed was then cooled to 25°C and transferred to clean pressure reactor, followed by addition of 6.8 gm (0.069 moles) of 2-methylpyrazol-3-ol, 2.07 gm (0.013 moles) of Sodium iodide, 0.72 gm (0.0027 moles) of Triphenylphosphine and 130 gm 1,4-dioxane.
  • This reaction mixture was flushed with carbon monoxide gas, heated and stirred at 60°C for 30 min under carbon monoxide atmosphere. The reaction mixture was later cooled to 30°C.
  • the reaction mixture was then cooled to 20°C within 3- 4 hours and the product was separated by filtration. The filtered product was then dried at 70-75°C under vacuum for 12 hours.
  • the isolated product i.e. [3-(4,5-dihydroisoxazol-3-yl)- 2-methyl-4-methylsulfonyl-phenyl]-(5-hydroxy-1-methyl-pyrazol-4-yl)methanone
  • Example 2 Preparation of [3-(4,5-dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]- (5-hydroxy-1-methyl-pyrazol-4-yl)methanone
  • a pressure reactor was charged with 22 gm (0.069 moles) of 3-(3-bromo-2-methyl-6- methylsulfonyl-phenyl)-4,5-dihydroisoxazole followed by 180 gm 1,4-dioxane, 17.6 gm (0.12 moles) of Potassium Carbonate, 0.72 gm (0.0027 moles) of triphenylphosphine and 6.8 gm (0.069 moles) of 2-methylpyrazol-3-ol.
  • This reaction mixture was flushed with carbon monoxide gas then heated and stirred at 60°C for 30 min under carbon monoxide atmosphere.
  • the reaction mixture was cooled to 30°C and 0.071 gm (0.0004 moles) Palladium Chloride catalyst was added to the reaction mixture and the reaction mass was flushed with carbon monoxide gas.
  • the reaction mixture was heated to 120°C under pressure of 15 bar of carbon monoxide gas for 20 hours.
  • the reaction mass was then cooled to 60°C followed by depressurizing the reactor. Further 200 gm of DM water was added to reaction mixture followed by 0.7 gm activated carbon and the reaction mixture was filtered through the celite bed to remove catalyst and the bed was washed with 100 gm water.
  • the main filtrate and the washings were combined and were concentrated to remove 1,4-dioxane and water.
  • the concentrated reaction mass was then diluted with 125 gm methanol and further the reaction mixture was heated to 60°C and the pH of reaction mixture was adjusted to 1.5 using 35% hydrochloric acid.
  • the reaction mixture was then cooled to 20°C over a period of 3-4 hours and the product was separated by filtration.
  • the filtered product was then dried at 70-75°C under vacuum for 12 hours.
  • the isolated product i.e.

Abstract

The present invention relates to a process for preparation of heteroarylketones of formula (I). The invention relates to an efficient process for the preparation of heteroarylketones for formula (I) which find use as herbicides. (I)

Description

PROCESS FOR THE PREPARATION OF HETEROARYLKETONES FIELD OF THE INVENTION The present invention relates to a process for the preparation of heteroarylketones of the formula (I). The invention relates to an efficient process for the preparation of heteroarylketones of the formula (I) which are used as herbicides.
Figure imgf000002_0001
BACKGROUND OF THE INVENTION Heteroarylketones of formula (I) are described in WO96/26206 and WO98/31681. The heteroarylketones of formula (I) are directed to an herbicidal compound 4-[3-(4,5-dihydro- 1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1H-pyrazol-3-one or [3-(4,5- dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]-(5-hydroxy-1-methyl-pyrazol-4- yl)methanone. WO 96/26206 discloses a process for preparing 4-(3-(4,5-dihydroisoxazol-3-yl) benzoyl)-5- hydroxypyrazoles where, in the last step, a 5-hydroxypyrazole is reacted with a 3-(4,5- dihydroisoxazol-3-yl) benzoic acid derivative. The 3-(4,5-dihydroisoxazol-3-yl) benzoic acid derivative required for this process can only be obtained with difficulty, via several steps. Accordingly, the process is relatively expensive and not optimal economically. DE 19709118 describes a process for preparing 3-(4,5-dihydroisoxazol-3-yl) benzoic acids starting from 3-bromo-(4,5-dihydroisoxazol-3-yl) benzene, Grignard reagents and carbon dioxide. WO 99/58509 describes a process for preparing 3-heterocyclyl-substituted benzoyl derivatives with reduced steps. However, the yields obtained by the process are not satisfactory.
The known prior art describe processes to synthesize 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2- methyl-4-methylsulfonylbenzoyl]-2-methyl-1H-pyrazol-3-one from a compound of formula (III). However, there are several disadvantages in terms of reaction conditions, the yields and/or work-up requirements rendering them unsuitable for industrial scale production. Another disadvantage of the processes described in the prior art is the formation of impurities which lead to further reduction of the yield. An object of the presently claimed invention is to provide an improved process for the synthesis of heteroaryl ketones that have herbicidal activity. Furthermore, the object underlying the presently claimed invention is to optimize the synthesis of heteroarylketones of formula (I). The present invention includes several advantages, for example, a more efficient process having minimal waste throughput and waste treatment. The presently claimed process is shown to avoid the need for carefully controlled reaction conditions, tedious multiple purification techniques, and the use of stoichiometric amounts of organometallic reagents. Description This object is achieved by the processes described in detail hereafter. A first aspect of the present invention relates to a process for the preparation of a compound of the general formula (I) or its salts as describes in step (A). Step (A): The process for the preparation of a compound of the general formula (I) or its salts
Figure imgf000003_0001
wherein
R1 is C1-C4 alkyl, R2 is Cl or C1-C4 alkyl, 3 is hydrogen or C1-C4 alkyl and 4 is C1-C4 alkyl, comprising at least the step of reacting a compound of formula (II),
Figure imgf000003_0002
wherein
R1 is C1-C4 alkyl and M is H or an alkali metal atom with a compound of formula
Figure imgf000004_0001
wherein
X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, and R4 is C1-C4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound. Step B: Further, the compound of general formula (III) is obtained by one or more of the following steps: a) reacting a nitro-methylphenyl compound of formula IV,
Figure imgf000004_0002
wherein R2 is Cl or C1-C4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
Figure imgf000005_0003
wherein R2 is Cl or C1-C4 alkyl, a) cyclization of the oxime of the formula (V) with an alkene of the formula (VI),
Figure imgf000005_0002
wherein R6, R7, R8 are, identical or different, hydrogen or C1-C4 alkyl, in the presence of at least one base to give a compound of formula (VII),
Figure imgf000005_0004
wherein R2 is Cl or C1-C4 alkyl and R3 is hydrogen or C1-C4 alkyl, b) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VIII),
Figure imgf000005_0001
Figure imgf000006_0002
wherein R2 is Cl or C1-C4 alkyl, and R3 is hydrogen or C1-C4 alkyl, c) substituting the para amino position in the compound of formula (VIII) to give the compound of formula (IX),
Figure imgf000006_0001
wherein R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3; d) reacting the compound of formula (IX) with a dialkyl disulfide of formula (X)
wherein R4 is C1-C4 alkyl,
Figure imgf000006_0003
in the presence of an organic nitrile of the formula R5-ONO, wherein R5 is n-butyl, and at least one catalyst to give the compound of formula (XI),
Figure imgf000006_0004
wherein R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl, and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3 e) oxidizing the compound of formula (XI) with at least one oxidizing agent to obtain the compound of formula (III),
Figure imgf000007_0001
wherein X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1- C4 alkyl, and R4 is C1-C4 alkyl, Salts of the compounds according to the invention can be formed in a customary manner, for example, by reacting the compound with an acid of the anion in question, if the compounds according to the invention have a basic functionality or by reacting acidic compounds according to the invention with a suitable base. Salts of the compounds prepared according to the invention are preferably agriculturally acceptable salts. The organic moieties or groups mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The term "Cv-Cw" indicates the number of carbon atom possible in each case. The term "halogen" refers to flouro, chloro, bromo and iodo. The term "C1-C4-alkyl" refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1,1-dimethylethyl. The term“substituted” if not specified otherwise refers to substituted with 1, 2 or maximum possible number of substituents. If substituents are more than one, then they are independently from each other are same or different, if not mentioned otherwise.
Meanings of the terms that are not defined herein are generally known to a person skilled in the art or in the literature. Preferred embodiments of the present invention are described below. Step (A) of the present invention for the preparation of a compound of the general formula (I) or its salts is as follows: Reacting a compound of formula (II), wherein
Figure imgf000008_0003
R1 is C1-C4 alkyl and M is H or an alkali metal atom with a compound of formula (III),
Figure imgf000008_0001
wherein
X is Cl, Br, I, S(=O) 2 3
2-CH3 or S(=O)2-CF3, R is Cl or C1-C4 alkyl, R is hydrogen or C1-C4 alkyl, and R4 is C1-C4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound to obtain a compound of formula (I)
Figure imgf000008_0002
wherein
R1 is C1-C4 alkyl, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl and R4 is C1-C4 alkyl. I n an embodiment, of the present invention R1 is C!_C2 alkyl, R2 is C1--C4 alkyl, R3 is hydrogen or C1--C4 alkyl, R4 is C1-C4 alkyl.
In another embodiment, of the present invention R1 is methyl, R2 is C1--C2 alkyl, R3 is hydrogen or C1-C4 alkyl and R4 is C1-C4 alkyl.
In another embodiment, of the present invention R1 is methyl, R2 is methyl, R3 is hydrogen or C1-C4 alkyl and R4 is C1-C4 alkyl.
In another embodiment, of the present invention R1 is methyl, R2 is methyl, R3 is hydrogen and R4 is C1-C4 alkyl.
In yet another embodiment, of the present invention R1 is methyl, R2 is methyl, R3 is hydrogen and R4 is C1--C2 alkyl.
I n another embodiment, of the present invention R1 is methyl, R2 is methyl, R3 is methyl and R4 is methyl.
In a preferred embodiment, of the present invention R1 is methyl, R2 is methyl, R3 is hydrogen and R4 is methyl.
The temperatures and the duration times of the reactions may be varied in broad ranges, which the person skilled in the art knows from analogous reactions. The temperatures often depend on the reflux temperature of the solvents or at higher temperature under pressure. The end of the reaction can be monitored by methods known to a person skilled in the art, for example, thin layer chromatography or H PLC or GC.
I n an embodiment, the mass ratio of reactant to solvent is in the range of 1: 5 to 1: 20,
In another embodiment, the mass ratio of reactant to solvent is in the range of 1:6 to 1:10.
If not otherwise indicated, the reactants can in principle be contacted with one another in any desired sequence.
The person skilled in the art also knows the best work-up of the reaction mixture after the end of the reaction.
In the present invention, step (A) takes place in the presence of at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound and at least one solvent, wherein the at least one metal is preferably in a form of a free state of formula M or in a form of a metal complex of formula M(L)n
In the following, preferred embodiments regarding step (A) of the invention are provided. It is to be understood that the preferred embodiments mentioned above and those still to be illustrated below of step (A) of the invention are to be understood as preferred alone or in combination with each other.
In one embodiment, the at least one alkali metal iodide is selected from the group consisting of sodium iodide, potassium iodide, lithium iodide. In a preferred embodiment, the at least one alkali metal iodide is sodium iodide. In one embodiment, the at least one metal (M) is selected from the group consisting of nickel (Ni), cobalt (Co), iron (Fe), ruthenium (Ru), rhodium (Rh), palladium (Pd), iridium (Ir), platinum (Pt), silver (Ag), copper (Cu), zinc (Zn), molybdenum (Mo) and tungsten (W). In preferred embodiment, the at least one metal (M) is selected from the group consisting of palladium (Pd), nickel (Ni), copper (Cu) and iron (Fe). In one embodiment, L, identical or different, is Cl, Br, I, P(C5-C14-aryl)m, P(C5-C12-heteroaryl)m, P(C5-C12-heteroaryl)m(C5-C14-aryl)3-m, CN, C1-C6-alkyl, C1-C6-alkyl-O-C1-C6-alkyl, -O-CO-C1- C6-alkyl, OH, nitro, -O-C1-C6-alkyl, C1-C4-haloalkoxy, C3-C8-cycloalkyl, C3-C8-halocycloalkyl, C3-C8-cycloalkenyl, C5-C14-aryl, C5-C14-aryl-(CH2)o-(Q)p-(CH2)o-C5-C14-aryl and 1,1ʼ- bis(diphenyl phosphino)ferrocene ; whereby Q represents a bridging group selected from the group consisting of -CR8R9, -O-, -S-, -NR10R11, -SiR12R13 and -CO-, wherein R8 and R9, identical or different, are hydrogen, C1-C12 alkyl, C5-C14-aryl or C5-C12-heteroaryl; wherein R10, R11, R12 and R13, identical or different, are hydrogen or C1-C4 alkyl or R10 together with R11 forms C5- C12-membered heterocycloalkyl, C5-C12-membered heterocycloalkenyl or C5-C12-membered heteroaryl and L is unsubstituted or further substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -NO2; -NR10R11, -P(phenyl)2, - OH, unsubstituted or substituted C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, unsubstituted or substituted C5-C14-aryl, unsubstituted or substituted C5-C12-heteroaryl, C5-C12-membered heterocycloalkyl, C5-C12 2-mmbered heterocycloalkenyl, -O-(CCH2r2)rr-O-, -C(=O)14, -C(=O)-O- R15
, -C=N-R16, SO3H, -O-C1-C6-alkyl and -O-Si-C1-C4-alkyl; wherein
R14 is hydrogen or C1-C4-alkyl;
R15 is hydrogen or C1-C4-alkyl;
R16 is hydrogen, C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C5-C14-aryl, C5-C12-heteroaryl or C3-C12-cycloalkyl;
n is 0,1,2,3,4,5 or 6
m is 1,2 or 3;
o is 0,1 or 2
p is 0,1 or 2 and
r is 1,2,3,4 or 5. In yet another embodiment, L is, identical or different, Cl, Br, I, P(C5-C14-aryl)m, CN, unsubstituted or substituted C1-C12-alkyl, C1-C4-alkoxy, C3-C8-cycloalkenyl, -O-CO-C1-C6- alkyl, C5-C14-aryl, 1,1ʼ- bis(diphenyl phosphino)ferrocene and C5-C14-aryl-(CH2)o-(Q)p-(CH2)o- C5-C14-aryl;
wherein
m is 1,2 or 3;
o is 0,1 or 2
p is 0,1 or 2. In more preferred embodiment, L is, identical or different, Cl, -OCOCH3, P(phenyl)3, P(o- tolyl)3, CN, dibenzylidene acetone, -CH3CN, 1,5-cyclooctadiene or 1,1ʼ- bis(diphenyl phosphino) ferrocene. In another embodiment, Ln is supported on silica gel, dendrimers, polystyrenes or mesoporous siliceous foam, for example as described in Vivek et. al., Tetrahedron, 63, 2007, 6949-6976. In another embodiment, R8 is hydrogen, C1-C12 alkyl, C5-C14-aryl or C5-C12-heteroaryl.
In another embodiment, R8 is hydrogen, methyl or ethyl.
In another embodiment, R9 is hydrogen, C1-C12 alkyl, C5-C14-aryl or C5-C12-heteroaryl.
In more preferred embodiment, R9 is hydrogen.
In another embodiment, R10 is hydrogen, methyl, ethyl, propyl or n-butyl.
In another embodiment, R1 1 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R12 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R13 is hydrogen, methyl, ethyl, propyl or butyl.
In another preferred embodiment, R13 is hydrogen, methyl or ethyl.
In yet another embodiment, R10 together with R11 forms C5-C12-membered heterocycloalkyl, C5-C12-membered heterocycloalkenyl or C5-C12-membered heteroaryl.
In another embodiment, R14 is hydrogen or C1-C4-alkyl.
In yet another embodiment, R14 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R15 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R16is hydrogen, C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C5-C14-aryl, C5-C12-heteroaryl or C3-C12-cycloalkyl.
In another embodiment, n is 0,1,2,3,4,5 or 6.
In yet another preferred embodiment, n is 0,1 or 2.
In yet another preferred embodiment, n is 3,4,5 or 6.
In more preferred embodiment, n is 2, 3 or 4.
In another embodiment, m is 1, 2 or 3.
In another embodiment, o is 0,1 or 2
In another embodiment, p is 0,1 or 2 and
In another embodiment, r is 1,2,3,4 or 5.
In more preferred embodiment, M, L and n are as follows in Table 1: Table 1
Figure imgf000011_0001
Figure imgf000012_0001
The amount of at least one M and/or MLn is in the ratio of 1: 100 mole to 1:500 mole of the compound of formula (III).
In a preferred embodiment the amount of at least one M and/or MLn is in the ratio of 1: 150 mole to 1:400 mole of the compound of formula (III)
In a preferred embodiment, the at least one metal catalyst is in a free state of palladium such as Pd/C.
In a preferred embodiment, the at least one metal catalyst is in a form of a metal complex selected from the group consisting of Pd(OCOCH3)2 and Pd(CI)2.
In one embodiment, the phosphine compound is PX1X2X3 or (PX1X2)2(B)q, whereby X1, X2and X3, identical or different, are F, Cl, Br, I, -NR17R18 hydrogen, -0-C1-C6-alkyl, -0-CO-C1-C6-alkyl, -C12-alkyl, C2-C6-alkenyl, C2-C6-al kyny I, C5-C14-aryl, C5-C12-heteroaryl, C3-C12-cycloalkyl, C3- C12-cycloalkenyl, C3-C12-heterocycloalkyl, C3-C12-heterocycloalkenyl or -Si-(C1--C12-alkyl)3, whereby B is CR19R20, -0-, -phenyl-O-phenyl-, -S-, -NR17R18, -Si R21R22 or -C(=O)-, wherein R19 and R20, identical or different, are hydrogen, C1-C12-a I ky I , C5-C14-aryl or C5-C12-heteroaryl, wherein R17, R18, R21 and R22, identical or different, are hydrogen or C1--C4-alkyl or R17 together with Reforms heterocycloalkyl, heterocycloalkenyl or C5-C12-heteroaryl; whereby X4, X2and X3 , identical or different, are unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -N02; -NR17R18, -P(phenyl)2, - OH, unsubstituted or substituted C1--C12-aI kyI , C2-C6-alkenyl, C2-C6-a I kyny I , unsubstituted or substituted C5-C14-aryl, unsubstituted or substituted C5-C12-heteroaryl, -0-(CH2)r-0-, - C(=O)R23_ -C(=O)-O-R24 -C=N-R25, -S03H, -O-C1-C6-alkyl and -O-Si- C1-C.4-alkyl, C5-C12- membered heterocycloalkyl, C5-C12-membered heterocycloalkenyl and C5-C12-heteroaryl; wherein q is 1,2, 3, 4, 5 or 6;
r is 1,2, 3, 4 or 5;
R23 is hydrogen or C4-C4-a I ky I ;
R24 is hydrogen or C4-C4-a I ky I ; and
R25 is hydrogen, C1--C12-a I ky I , C2-C6-alkenyl, C2-C6-a I kyny I , C5-C14-aryl, C5-C12-heteroaryl or C3- C12-cycloalkyl;
or their acceptable salts thereof.
In another embodiment, X4, X2and X3, identical or different, are C1--C12-a I kyl , C5-C14-aryl or C5- C12-heteroaryl.
In more preferred embodiment, X4, X2and X3, identical or different, are methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1- methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1- dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4- methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3- d i methyl butyl , 3,3-dimethylbutyl, 1-ethyl butyl, 2-ethyl butyl, 1,1,2-trimethyl propyl, 1,2,2- trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl, n-octyl, 1-methylpropyl, 2-methylheptyl or 1,1-dimethylethyl. In yet another preferred embodiment, X1, X2 and X3, identical or different, are phenyl or naphthyl. In yet another preferred embodiment, X1, X2 and X3, identical or different, are pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, thiadiazolyl, oxadiazolyl, and tetrazolyl rings, and the fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C8-C10 bicyclic group such as indolyl, benzimidazolyl, indazolyl, benzotriazolyl, isoquinolinyl, quinolinyl, benzothiazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, pyrazolopyridyl, quinazolinyl, quinoxalinyl or cinnolinyl. In another embodiment, R17 is hydrogen or C1-C4 alkyl.
In another embodiment, R17 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R18 is hydrogen, methyl, ethyl, propyl or butyl.
In another preferred embodiment, R18 is hydrogen.
In yet another embodiment, R17 together with R18 forms C5-C12-membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl or C5-C12-heteroaryl.
In another embodiment, R19 is hydrogen, C1-C12-alkyl, C5-C14-aryl or C5-C12-heteroaryl.
In yet another embodiment, R19 is hydrogen, methyl ethyl, propyl, phenyl or naphthyl.
In another embodiment, R20 is hydrogen, C1-C12-alkyl, C5-C14-aryl or C5-C12-heteroaryl.
In yet another embodiment, R20 is hydrogen, methyl ethyl, propyl or butyl.
In another embodiment, R21 is hydrogen or C1-C4 alkyl.
In another preferred embodiment, R21 is hydrogen.
In another embodiment, R22 is hydrogen, methyl, ethyl, propyl or butyl.
In yet another embodiment, R22 is hydrogen, methyl or ethyl.
In another embodiment, R23 is hydrogen or C1-C4-alkyl.
In another preferred embodiment, R23 is hydrogen, methyl, ethyl, propyl or butyl.
In another embodiment, R24 is hydrogen methyl, ethyl, propyl or butyl. In another embodiment, the at least one phosphine compound is selected from the group consisting of allyldiphenylphosphine; 1,3-bis(diphenylphosphino)propane; 1,3-bis(dicyclo- hexylphosphino)propane, 1,4-bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phos- phine, tri-tert-butylphosphine ,di-tert-butyl(phenyl)phosphine tetrafluoroborate; (2-am- monioethyl) di-tert-butylphosphonium bis(tetrafluoroborate); (2-ammonioethyl) diiso- propylphosphonium bis(tetrafluoroborate); (3-ammoniopropyl) di-tert-butylphosphonium bis(tetrafluoroborate); (3-ammoniopropyl) diisopropylphosphonium bis(tetrafluoroborate); bis(3,5-bis(trifluoromethyl)phenyl)(2¢,6¢-bis(isopropoxy)-3,6-dimethoxybiphenyl-2- yl)phosphine; benzyldiphenylphosphine; (2-biphenyl)di-1-adamantylphosphine; 1-[2- [bis(tert-butyl)phosphino]phenyl]-3,5-diphenyl-1H-pyrazole; bis[2-(diadaman- tylphosphino)ethyl]amine; 2-[bis(3,5-di-tert-butyl-4- methoxyphenyl)phosphino]benzaldehyde; 2,6-bis(di-tert-butylphosphinomethyl)pyridine; bis(dicyclohexylphosphinophenyl)ether; bis(diethylamino)phenylphosphine;
bis(dimethylamino)chlorophosphine; 2-[bis(3,5-dimethylphenyl)phosphino]benzaldehyde; bis[4-(3,3,4,4,5,5,5-heptafluoro-2,2-bis(trifluoromethyl)pentyl)phenyl]phenylphosphine; bis(2-methoxyphenyl)phosphine; bis[4-(1H,1H,2H,2H- perfluorodecyl)phenyl]phenylphosphine; 1,1¢-bis(phenylphosphinidene)ferrocene; (2- bromophenyl)dicyclohexylphosphine; (2-bromophenyl)diphenylphosphine; tert- butyldicyclohexylphosphine; tert-butyldicyclohexylphosphonium tetrafluoroborate; tert- butyldiisopropylphosphine; tert-butyldiphenylphosphine; 1-(dicyclohexylphosphino)-2,2- Diphenyl-1-methylcyclopropane; cyclohexyldiphenylphosphine; di(1-adamantyl)-2- dimethylaminophenylphosphine; di-1-adamantylphosphine; di(1-adamantyl)-(2- triisopropylsiloxyphenyl)phosphine; (5H-dibenzo[a,d]cyclohepten-5-yl)diphenylphosphine; di-tert-butylcyclohexylphosphine; di-tert-butyl N,N-diisopropylphosphoramidite; di-tert- butylmethylphosphine; di-tert-butyl(methyl)phosphonium tetrafluoroborate; di-tert- butyl(methyl)phosphonium tetrafluoroborate; di-tert-butylneopentylphosphine; di-tert- butylneopentylphosphonium tetrafluoroborate; di-tert-butylphenylphosphine; di-tert- butylphosphate potassium salt; 2¢-(di-tert-butylphosphino)acetophenone ethylene ketal; 2-(di-tert-butylphosphino)dimethylaminobenzene; 2-(di-tert-butylphosphino)ethylamine; 2- ((di-tert-butylphosphinomethyl)-6-diethylaminomethyl)pyridine; 5-(di-tert-butylphosphino)- 1-(naphthalen-1-yl)-1H-pyrazole; 5-(di-tert-butylphosphino)-1¢, 3¢, 5¢-triphenyl-1¢H- [1,4¢]bipyrazole; 3-(di-tert-butylphosphonium)propane sulfonate; P,P- dichloroferrocenylphosphine; dicyclohexyl-(2,6-diisopropylphenyl)phosphine;
dicyclohexyl(4-(N,N-dimethylamino)phenyl)phosphine; dicyclohexyl(ethyl)phosphine;
dicyclohexyl(4-isopropylphenyl)phosphine; dicyclohexyl(2-methylphenyl)phosphine;
dicyclohexylphenylphosphine; 2¢-(dicyclohexylphosphino)acetophenone ethylene ketal; 2- (dicyclohexylphosphino)benzophenone; 2-(dicyclohexylphosphino)-N,N-diisopropyl-1H- indole-1-carboxamide; N -(dicyclohexyl phosphino)-2-(2¢-methoxyphenyl)indole; 2- [(dicyclohexylphosphino)methyl]-1,3-bis(2,6-diisopropylphenyl)-4,5-dimethylimidazolium iodide; 2-(2-dicyclohexylphosphinophenyl)-1,3-dioxolane; 2-[2- (dicyclohexylphosphino)phenyl]-N-methylindole; dicyclohexyl(2,4,6- trimethylphenyl)phosphine; diethylphenylphosphine; diethylphosphine; 4- (diethylphosphino)-N,N-dimethylaniline; 9-[2-(diisopropylphosphino)phenyl]-9H-carbazole; 2-[di(2-methoxyphenyl)phosphino]benzenesulfonic acid;
dimethylaminophenylchlorophosphine; 4-(dimethylamino)phenyldiphenylphosphine; 2-(1,1- dimethylpropyl)-6-(diphenylphosphino)pyridine; diphenyl(2-methoxyphenyl)phosphine; 4- diphenylphosphanylbenzoic acid; 2-(diphenylphosphino)benzaldehyde; 2- (diphenylphosphino)benzaldehyde oxime; 3-(diphenylphosphino)benzenesulfonic acid sodium salt; 2-(diphenylphosphino)benzoic acid; 4-(diphenylphosphino)benzoic acid; N-[2- (diphenylphosphino)benzylidene] cyclohexylamine; 2-(diphenylphosphino)-N,N- dimethylbenzylamine; 2-(diphenylphosphino)ethanaminium tetrafluoroborate; 2- (diphenylphosphino)ethylamine; 2-(2-(diphenylphosphino)ethyl)pyridine; 3- (diphenylphosphino)propan-1-aminium tetrafluoroborate; 3-(diphenylphosphino)-1- propylamine; 4-(diphenylphosphino) styrene; 2-(diphenylphosphino)-N,N,N- trimethylbenzylammonium triflate;diphenyl-2-pyridylphosphine; diphenyl(o-tolyl)phosphine; diphenyl(p-tolyl)phosphine; diphenylvinylphosphine; 2-(di-p-tolylphosphino)benzaldehyde; ethyldiphenylphosphine; [4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyl)phenyl] diphenylphosphine; (4-hydroxyphenyl)diphenylphosphine; isopropyldiphenylphosphine; 1-methyl-2-(2-dicyclohexylphosphinophenyl)-1H- benzoimidazole; 1-methyl-2-(2-diisopropylphosphinophenyl)-1H-benzoimidazole;
methyldiphenylphosphine; 1-methyl-2-(2-diphenylphosphinophenyl)-1H-benzoimidazole; 1,2,3,4,5-pentaphenyl-1¢-(di-tert-butylphosphino)ferrocene; phenylbis[4- (3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)phenyl]phosphine; phenyldi(o-tolyl)phosphine; phenylphosphine; 4,4¢-(phenylphosphinidene)bis(benzenesulfonic acid) dipotassium salt hydrate; tetrapropylphosphonium bromide; triallylphosphine; tribenzylphosphine;
tributylphosphine; tri-n-butylphosphine; tri-tert-butylphosphine; tri-tert-butylphosphine; tri- tert-butylphosphine; tributylphosphine tetrafluoroborate; tri-tert-butylphosphonium tetrafluoroborate; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine tetrafluoroborate; tricyclopentylphosphine; tricyclopentylphosphine tetrafluoroborate; triethylphosphine; triethylphosphine; ((4-trifluoromethyl)phenyl)di-tert- butylphosphine, tri(2-furyl)phosphine; ((2,4,6-tri-isopropyl)phenyl)di-cyclohexylphosphine; triisopropylphosphine; triisopropylphosphonium tetrafluoroborate; trimethylphosphine;
trimethylphosphonium tetrafluoroborate; tri-1-naphthylphosphine; trioctylphosphine;
triphenylphosphine; triphenylphosphine hydrobromide; 4-(triphenylphosphonio)butane-1- sulfonate; tripropylphosphine; tris[3,5-bis(trifluoromethyl)phenyl]phosphine; tris(4- chlorophenyl)phosphine; tris(diethylamino)phosphine; tris(2,6-dimethoxyphenyl)phosphine; tris(dimethylamino)phosphine; tris(3,5-dimethylphenyl)phosphine; tris(2,4-dimethyl-5- sulfanatophenyl)phosphine trisodium salt; tris[2-(diphenylphosphino)ethyl]phosphine;
tris(4-fluorophenyl)phosphine; tris[4-(heptadecafluorooctyl)phenyl]phosphine;
tris(hydroxymethyl)phosphine; tris(4-methoxy-3,5-dimethylphenyl)phosphine; tris(o- methoxyphenyl)phosphine; tris(4-methoxyphenyl)phosphine; tris(4-methyl-1- piperazinyl)phosphine; tris(pentafluorophenyl)phosphine; tris(1-pyrrolidinyl)phosphine; tris[4-(tridecafluorohexyl)phenyl]phosphine; tris[4-(3,3,4,4,5,5,6,6,7,7,8,8,8- tridecafluorooctyl)phenyl]phosphine; tris(4-trifluoromethylphenyl)phosphine; tris(2,4,6- trimethoxyphenyl)phosphine; tris(2,4,6-trimethylphenyl)phosphine;
tris(trimethylsilyl)phosphine; tri(o-tolyl)phosphine; tri(p-tolyl)phosphine; tri-o- tolylphosphine tetrafluoroborate; and 2-(dicyclohexylphosphino)-3,6-dimethoxy- 2¢,4¢,6¢-triisopropyl-1,1¢-biphenyl or acceptable salts thereof. In another preferred embodiment, the at least one phosphine compound is selected from the group consisting of triphenylphosphine, 1,3-bis(dicyclohexylphosphino)propane, 1,4- bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phosphine and tri-tert-butylphosphine. In an embodiment, the mole ratio of at least one phosphine compound to the at least one metal catalyst is in the range of 1:0.010 to 1:0.20
In another embodiment, the mole ratio of at least one phosphine compound to the at least one metal catalyst is in the range of 1:0.025 to1:0.175.
In a most preferred embodiment, the mole ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.05 to1:0.160 In a most preferred embodiment, the mole ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.075 to 1:0.15.
In an embodiment, reaction temperature of the step (A) is kept within a range of from 50oC to 150°C, preferably in the range of from 50°C to 130°C, more preferably in the range of from 55°C to 120°C.
In an embodiment, the reaction of the step (A) is carried out at of pressure of 5 bar to 20 bar, preferably in the range of from 7 bar to 15 bar, more preferably in the range of 9 bar to 15 bar. In an embodiment, the at least one solvent of step (A) is selected from the group consisting of esters, ethers, aromatic hydrocarbons and acetals. In one embodiment, the solvent of step (A) is triethylorthoformate, trimethylorthoformate, tripropylorthoformate, tributylorthoformate, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4- dioxane, diethyl ether, diisopropyl ether, di-n-propyl ether, di-n-butyl ether, methyl-tert-butyl ether, diisobutyl ether, tetrahydropyran, dimethoxymethane, dimethoxypropane, dimethoxybutane, toluene, xylene, cyclohexane and monochlorobenzene. In an embodiment, the at least one base in step (A) is selected from organic bases or inorganic bases. In an embodiment, the organic bases are selected from the group consisting of N(R27)3, N- methyl piperidine, N-methyl pyrrolidine, N-methyl morpholine, piperidine, dimethyl amino pyridine, pyridine, lithium hexamethyldisilazide, sodium hexamethyldisilazide and tetra-C1- C6-alkyl ammonium hydroxide, wherein R27 is, identical or different, hydrogen, C1-C6-alkyl, C5- C14-aryl, or C3-C6-cycloalkyl. In an embodiment, the inorganic bases are selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide. In another embodiment,the alkali metal hydroxide is selected from group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide and cesium hydroxide; the alkaline earth hydroxide is selected from the group consisting of magnesium hydroxide, calcium hydroxide, strontium hydroxide and barium hydroxide; the alkali metal bicarbonate is selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, rubidium bicarbonate and cesium bicarbonate; the alkaline earth bicarbonate is selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, strontium bicarbonate and barium bicarbonate; the alkali metal carbonate is selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, rubidium carbonate and cesium carbonate; the alkaline earth carbonate is selected from group the consisting of magnesium carbonate, calcium carbonate, strontium carbonate and barium carbonate; the alkali metal phosphate is selected from the group consisting of monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate; the alkali metal alkoxide is selected from the group consisting of NaOR28, KOR28, RbOR28 and CsOR28; the alkaline earth alkoxide is selected from the group consisting of Mg(OR28)2, Ca(OR28)2 and Ba(OR28)2; wherein R28 is, identical or different, C1-C4-alkyl. In a preferred embodiment, the at least one inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate. In a most preferred embodiment, the at least one base is selected from the group consisting of potassium carbonate, 4-dimethylaminopyridine and triethylamine. Step (B) of the present invention for the preparation of a compound of the general formula (III) is as follows and involves the steps from a) to f) a) reacting a nitro-methylphenyl compound of formula IV,
Figure imgf000017_0001
(IV),
wherein R2 is Cl or C1-C4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
Figure imgf000017_0002
wherein R2 is Cl or C1-C4 alkyl, b) cyclization of the oxime of the formula (V) with an alkene of the formula (VI), (VI), wherein R6, R7, R8 are, identical or different, hydrogen or C1-C4 alkyl, in the presence of at least one base to give a compound of formula (VII),
Figure imgf000018_0001
(VII),
wherein R2 is Cl or C1-C4 alkyl and R3 is hydrogen or C1-C4 alkyl, c) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VIII),
Figure imgf000018_0002
(VIII),
wherein R2 is Cl or C1-C4 alkyl, and R3 is hydrogen or C1-C4 alkyl, d) substituting the para amino position in the compound of formula (VIII) to give the compound of formula (IX),
Figure imgf000019_0002
wherein R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl and X is Cl, Br, I, S(=0)2-CH3 or S(=O)2-CF3; e) reacting the compound of formula (IX) with a dialkyl disulfide of formula (X)
Figure imgf000019_0003
wherein R4 is C1-C4 alkyl,
in the presence of an organic nitrile of the formula R5-ONO, wherein R5 is n-butyl, and at least one catalyst to give the compound of formula (XI),
Figure imgf000019_0001
wherein R2 is Cl or Ci-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl, and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3 f) oxidizing the compound of formula (XI) with at least one oxidizing agent to obtain the compound of formula (I II),
Figure imgf000019_0004
wherein X is Cl, Br, I, S(=0)2-CH3 or S(=0)2-CF3, R2 is Cl or Ci-C4 alkyl, R3 is hydrogen or Cl- C4 alkyl, and R4 is Ci-C4 alkyl,
In an embodiment, R1 is C1_C2 alkyl, R2 is C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl.
In another embodiment, R1 is methyl, R2 is C1-C2 alkyl, R3 is hydrogen or C1-C4 alkyl, R4 is C1- C4 alkyl.
In another embodiment, R1 is methyl, R2 is methyl, R3 is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl.
In another embodiment, R1 is methyl, R2 is methyl, R3 is hydrogen, R4 is C1-C4 alkyl.
In yet another embodiment, R1 is methyl, R2 is methyl, R3 is hydrogen, R4 is C1-C2 alkyl.
In another embodiment, R1 is methyl, R2 is methyl, R3 is methyl, R4 is methyl.
In a preferred embodiment, R1 is methyl, R2 is methyl, R3 is hydrogen, R4 is methyl.
In an embodiment, R6, R7, R8 are, identical or different, hydrogen or C1 C4 alkyl
In another embodiment, R6, R7, R8 are, identical or different, hydrogen or C1-C2 alkyl
In an embodiment, X is Cl, Br, I, S(=0)2-CH3 or S(=0)2-CF3.
In yet another embodiment, X is Cl, Br, l,-CF3.
In a preferred embodiment, X is Cl, Br.
In a most preferred embodiment, X is Br.
In an embodiment, step (B) takes place in the presence of at least one base, at least one metal catalyst and at least one solvent.
In an embodiment, the at least one base used in step (B) is selected from the group of tertiary amines, for example triethylamine, cyclic amines, such as N-methylpiperidine or N,N'- dimethylpiperazine, pyridine, alkali metal carbonates, for example sodium carbonate or potassium carbonate, alkali metal bicarbonates, for example sodium bicarbonate or potassium bicarbonate, alkaline earth metal carbonates, for example calcium carbonate, and alkali metal hydroxides, for example sodium hydroxide or potassium hydroxide.
In an embodiment, the at least one metal catalyst in step (B) is Ni, Pt/C, Pd/C, copper powder, elemental copper in a different form, such as, for example, turnings, wire, granules, pellets, rods; copper(l) salts, for example copper(l) chloride, copper(l) bromide or copper(l) iodide, copper(ll) salts, or elemental iodine.
In an embodiment, the at least one solvent in step (B) is a haloalkane, such as 1,2- dichloroethane or methylene chloride; aromatic compounds, such as benzene, toluene, chlorobenzene, nitrobenzene or xylene; polar aprotic solvents, for example N,N- dialkylformamides, N,N-dialkylacetamides, N-methylpyrrolidone, dimethylpropyleneurea; tetramethylurea, acetonitrile, propionitrile; alcohols, such as methanol, ethanol, n-propanol or isopropanol; carboxylic acids, such as acetic acid or propionic acid; carboxylic esters, such as ethyl acetate. In the following, there is provided a list of embodiments to further illustrate the present disclosure without intending to limit the disclosure to the specific embodiments listed below. 1. A process for the preparation of a compound of the general formula (I) or its salts,
Figure imgf000021_0001
wherein
R1 is C1-C4 alkyl, R2 is Cl or C 3
1-C4 alkyl, R is hydrogen or C1-C4 alkyl and R4 is C1-C4 alkyl, comprising at least the step of reacting a compound of formula (II),
Figure imgf000021_0002
wherein
R1 is C1-C4 alkyl and M is H or an alkali metal atom with a compound of formula (III),
Figure imgf000021_0003
wherein X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, and R4 is C1-C4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound. 2. The process according to embodiment 1, wherein the compound of general formula (III) is obtained by one or more of the following steps: a) reacting a nitro-methylphenyl compound of formula IV,
wherein R2 is Cl or C1-C4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
wherein R2 is Cl or C1-C4 alkyl, b) cyclization of the oxime of the formula (V) with an alkene of the formula (VI),
wherein R6, R7, R8 are, identical or different, hydrogen or C1-C4 alkyl, in the presence of at least one base to give a compound of formula (VII),
wherein R2 is Cl or C1-C4 alkyl and R3 is hydrogen or C1-C4 alkyl, c) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VI II),
Figure imgf000023_0001
wherein R2 is Cl or C1-C4 alkyl, and R3 is hydrogen or C1-C4 alkyl, d) substituting the para amino position in the compound of formula (VI II) to give the compound of formula (IX),
Figure imgf000023_0002
wherein R2 is Cl or C1-C4 alkyl, R3 is hydrogen or Ci-C4 alkyl and X is Cl, Br, I, S(=0)2-CH3 or S(=0)2-CF3; e) reacting the compound of formula (IX) with a dialkyl disulfide of formula (X) wherein R4 is C1-C4 alkyl,
in the presence of an organic nitrile of the formula R5-ONO, wherein R5 is n-butyl, and at least one catalyst to give the compound of formula (XI),
Figure imgf000024_0001
wherein R2 is Cl or C 3
1-C4 alkyl, R is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl, and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3 f) oxidizing the compound of formula (XI) with at least one oxidizing agent to obtain the compound of formula (III),
Figure imgf000024_0002
wherein X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3, R is Cl or C1-C4 alkyl, R is hydrogen or C1- C4 alkyl, and R4 is C1-C4 alkyl,
3. The process according to embodiments 1 or 2, wherein R1, R2 and R4 are each methyl and R3 is hydrogen. 4. The process according to embodiment 1, wherein the alkali metal iodide is selected from the group consisting of sodium iodide, potassium iodide and lithium iodide. form of a free state of formula M or in a form of a metal complex of formula M(L)n, wherein
M is selected from the group consisting of nickel (Ni), cobalt (Co), iron (Fe), 5 ruthenium (Ru), rhodium (Rh), palladium (Pd), iridium (Ir), platinum (Pt), silver (Ag), copper (Cu), zinc (Zn), molybdenum (Mo) and tungsten (W);
L is, identical or different, selected from the group consisting of Cl, Br, I, P(C5-C14- aryl)m, P(C5-C12-heteroaryl)m, P(C5-C12-heteroaryl)m(C5-C14-aryl)3-m, CN, C1-C6-alkyl, C1- C6-alkyl-O-C1-C6-alkyl, -O-CO-C1-C6-alkyl, OH, nitro, -O-C1-C6-alkyl, C1-C4-haloalkoxy,10 C3-C8-cycloalkyl, C3-C8-halocycloalkyl, C3-C8-cycloalkenyl, C5-C14-aryl, C5-C14-aryl- (CH2)o-(Q)p-(CH2)o-C5-C14-aryl and 1,1ʼ- bis(diphenyl phosphino)ferrocene ; whereby Q represents a bridging group selected from the group consisting of -CR9R10, -O-, -S-, - NR11R12, -SiR13R14 and -CO-, wherein R9 and R10, identical or different, are hydrogen, C1- C1 alkyl, C5-C14-aryl or C5-C12-heteroaryl; wherein R11, R12, R13 and R14 2 , identical or 15 different, are hydrogen or C1-C4 alkyl or R11 together with R12 forms C5-C12-membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl or C5-C12-membered heteroaryl; and L is unsubstituted or further substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -NO2; -NR10R11, -P(phenyl)2, -OH, unsubstituted or substituted C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, unsubstituted or20 substituted C5-C14-aryl, unsubstituted or substituted C5-C12-heteroaryl, C5-C12- membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl, -O-(CH2)r-O-, - C(=O)R15
, -C(=O)-O-R16
, -C=N-R17, -SO3H, -O-C1-C6-alkyl and -O-Si-C1-C4-alkyl; or L is supported on silica gel, dendrimers, polystyrenes or mesoporous siliceous foam,
25 wherein
R15 is hydrogen or C1-C4-alkyl;
R16 is hydrogen or C1-C4-alkyl;
R17 is hydrogen, C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C5-C14-aryl, C5-C12-heteroaryl or C3-C12-cycloalkyl;
30 n is 0, 1, 2, 3, 4, 5 or 6;
m is 1,2 or 3;
o is 0,1 or 2
p is 0,1 or 2 and
r is 1,2,3,4 or 5,
35 or their acceptable salts thereof. 6. The process according to embodiment 5, wherein M is selected from the group consisting of nickel (Ni), iron (Fe), palladium (Pd) and copper (Cu). 40 7. The process according to embodiment 5, wherein L is, identical or different, selected from the group consisting of Cl, Br, I, P(C5-C14-aryl)m, CN, unsubstituted or substituted C1-C12-alkyl, C1-C4-alkoxy, C3-C8-cycloalkenyl, -O-CO-C1-C6-alkyl, C5-C14-aryl, 1,1ʼ- bis(diphenyl phosphino)ferrocene and C5-C14-aryl-(CH2)o-(Q)p-(CH2)o-C5-C14-aryl, whereby m, o, Q and p are as defined as in claim 7. 8. The process according to embodiment 5, wherein the metal complex of formula M(L)n is selected from the group consisting of Pd(OCOCH3)2, PdCl2, PdCl2 (CH3CN)2, Pd (1,1ʼ- bis(diphenyl phosphino)ferrocene)Cl2, Pd2(dibenzylideneacetone)3 and
Pd(dibenzylideneacetone)2. 9. The process according to embodiments 5 to 8, wherein the at least one metal catalyst is in a form of a free state of palladium such as Pd/C or in a form of a metal complex selected from the group consisting of Pd(OCOCH3)2 and PdCl2. 10. The process according to embodiment 1, wherein the at least one phosphine compound is of the formula PX1X2X3 or (PX1X2)2(B)q, whereby X1, X2 and X3, identical or different, are F, Cl, Br, I, -NR18R19
, hydrogen, -O-C1-C6-alkyl, -O-CO-C1-C6-alkyl, C1-C12-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C5-C14-aryl, C5-C12-heteroaryl, C3-C12-cycloalkyl, C3-C12- cycloalkenyl, C3-C12-heterocycloalkyl, C3-C14-heterocycloalkenyl or -Si-(C1-C12-alkyl)3, whereby B is CR20R21, -O-, -phenyl-O-phenyl-, -S-, -NR18R19, -SiR22R23 or -C(=O)-, wherein R20 and R21, identical or different, are hydrogen, C1-C12-alkyl, C5-C14-aryl or C5- C 1
12-heteroaryl, wherein R18, R19, R20 and R2 , identical or different, are hydrogen or C1- C4-alkyl or R18 together with R19 forms C5-C12-membered heterocycloalkyl, C5-C14- membered heterocycloalkenyl or C5-C12-heteroaryl; whereby X1, X2 and X3 , identical or different, are unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -NO2; -NR18R19, -P(phenyl)2, -OH, unsubstituted or substituted C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, unsubstituted or substituted C5-C14-aryl, unsubstituted or substituted C5-C12-heteroaryl, -O-(CH2)r-O-, - C(=O)R24
, -C(=O)-O-R25
, -C=N-R26, -SO3H, -O-C1-C6-alkyl and -O-Si-C1-C4-alkyl, C5-C12- membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl and C5-C12- heteroaryl;
wherein q is 1, 2, 3, 4, 5 or 6;
r is 1, 2 ,3, 4 or 5;
R24 is hydrogen or C1-C4-alkyl;
R25 is hydrogen or C1-C4-alkyl; and
R26 is hydrogen, C1-C12-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C5-C14-aryl, C5-C12 heteroaryl or C3-C12-cycloalkyl;
or their acceptable salts thereof. 11. The process according to embodiment 10, wherein the at least one phosphine
compound is selected from the group consisting of allyldiphenylphosphine; 1,3- bis(diphenylphosphino)propane; 1,3-bis(dicyclohexylphosphino)propane, 1,4- bis(diphenylphosphino)butane, di-tert-butyl(phenyl)phosphine , tri-tert- butylphosphine ,di-tert-butyl(phenyl)phosphine tetrafluoroborate; (2-ammonioethyl) di-tert-butylphosphonium bis(tetrafluoroborate); (2-ammonioethyl)
diisopropylphosphonium bis(tetrafluoroborate); (3-ammoniopropyl) di-tert- butylphosphonium bis(tetrafluoroborate); (3-ammoniopropyl) diisopropylphosphonium bis(tetrafluoroborate); bis(3,5-bis(trifluoromethyl)phenyl)(2¢,6¢-bis(isopropoxy)-3,6- dimethoxybiphenyl-2-yl)phosphine; benzyldiphenylphosphine; (2-biphenyl)di-1- adamantylphosphine; 1-[2-[bis(tert-butyl)phosphino]phenyl]-3,5-diphenyl-1H- pyrazole; bis[2-(diadamantylphosphino)ethyl]amine; 2-[bis(3,5-di-tert-butyl-4- methoxyphenyl)phosphino]benzaldehyde; 2,6-bis(di-tert- butylphosphinomethyl)pyridine; bis(dicyclohexylphosphinophenyl)ether;
bis(diethylamino)phenylphosphine; bis(dimethylamino)chlorophosphine; 2-[bis(3,5- dimethylphenyl)phosphino]benzaldehyde; bis[4-(3,3,4,4,5,5,5-heptafluoro-2,2- bis(trifluoromethyl)pentyl)phenyl]phenylphosphine; bis(2-methoxyphenyl)phosphine; bis[4-(1H,1H,2H,2H-perfluorodecyl)phenyl]phenylphosphine; 1,1¢- bis(phenylphosphinidene)ferrocene; (2-bromophenyl)dicyclohexylphosphine; (2- bromophenyl)diphenylphosphine; tert-butyldicyclohexylphosphine; tert- butyldicyclohexylphosphonium tetrafluoroborate; tert-butyldiisopropylphosphine; tert- butyldiphenylphosphine; 1-(dicyclohexylphosphino)-2,2-Diphenyl-1- methylcyclopropane; cyclohexyldiphenylphosphine; di(1-adamantyl)-2- dimethylaminophenylphosphine; di-1-adamantylphosphine; di(1-adamantyl)-(2- triisopropylsiloxyphenyl)phosphine; (5H-dibenzo[a,d]cyclohepten-5- yl)diphenylphosphine; di-tert-butylcyclohexylphosphine; di-tert-butyl N,N- diisopropylphosphoramidite; di-tert-butylmethylphosphine; di-tert- butyl(methyl)phosphonium tetrafluoroborate; di-tert-butyl(methyl)phosphonium tetrafluoroborate; di-tert-butylneopentylphosphine; di-tert- butylneopentylphosphonium tetrafluoroborate; di-tert-butylphenylphosphine; di-tert- butylphosphate potassium salt; 2¢-(di-tert-butylphosphino)acetophenone ethylene ketal; 2-(di-tert-butylphosphino)dimethylaminobenzene; 2-(di-tert- butylphosphino)ethylamine; 2-((di-tert-butylphosphinomethyl)-6- diethylaminomethyl)pyridine; 5-(di-tert-butylphosphino)-1-(naphthalen-1-yl)-1H- pyrazole; 5-(di-tert-butylphosphino)-1¢, 3¢, 5¢-triphenyl-1¢H-[1,4¢]bipyrazole; 3- (di-tert-butylphosphonium)propane sulfonate; P,P-dichloroferrocenylphosphine;
dicyclohexyl-(2,6-diisopropylphenyl)phosphine; dicyclohexyl(4-(N,N- dimethylamino)phenyl)phosphine; dicyclohexyl(ethyl)phosphine; dicyclohexyl(4- isopropylphenyl)phosphine; dicyclohexyl(2-methylphenyl)phosphine;
dicyclohexylphenylphosphine; 2¢-(dicyclohexylphosphino)acetophenone ethylene ketal; 2-(dicyclohexylphosphino)benzophenone; 2-(dicyclohexylphosphino)-N,N- diisopropyl-1H-indole-1-carboxamide; N -(dicyclohexyl phosphino)-2-(2¢- methoxyphenyl)indole; 2-[(dicyclohexylphosphino)methyl]-1,3-bis(2,6- diisopropylphenyl)-4,5-dimethylimidazolium iodide; 2-(2- dicyclohexylphosphinophenyl)-1,3-dioxolane; 2-[2-(dicyclohexylphosphino)phenyl]-N- methylindole; dicyclohexyl(2,4,6-trimethylphenyl)phosphine; diethylphenylphosphine; diethylphosphine; 4-(diethylphosphino)-N,N-dimethylaniline; 9-[2- (diisopropylphosphino)phenyl]-9H-carbazole; 2-[di(2- methoxyphenyl)phosphino]benzenesulfonic acid;
dimethylaminophenylchlorophosphine; 4-(dimethylamino)phenyldiphenylphosphine; 2- (1,1-dimethylpropyl)-6-(diphenylphosphino)pyridine; diphenyl(2- methoxyphenyl)phosphine; 4-diphenylphosphanylbenzoic acid; 2- (diphenylphosphino)benzaldehyde; 2-(diphenylphosphino)benzaldehyde oxime; 3- (diphenylphosphino)benzenesulfonic acid sodium salt; 2-(diphenylphosphino)benzoic acid; 4-(diphenylphosphino)benzoic acid; N-[2-(diphenylphosphino)benzylidene] cyclohexylamine; 2-(diphenylphosphino)-N,N-dimethylbenzylamine; 2- (diphenylphosphino)ethanaminium tetrafluoroborate; 2- (diphenylphosphino)ethylamine; 2-(2-(diphenylphosphino)ethyl)pyridine; 3- (diphenylphosphino)propan-1-aminium tetrafluoroborate; 3-(diphenylphosphino)-1- propylamine; 4-(diphenylphosphino) styrene; 2-(diphenylphosphino)-N,N,N- trimethylbenzylammonium triflate;diphenyl-2-pyridylphosphine; diphenyl(o- tolyl)phosphine; diphenyl(p-tolyl)phosphine; diphenylvinylphosphine; 2-(di-p- tolylphosphino)benzaldehyde; ethyldiphenylphosphine; [4- (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl] diphenylphosphine; (4-hydroxyphenyl)diphenylphosphine; isopropyldiphenylphosphine; 1-methyl-2-(2- dicyclohexylphosphinophenyl)-1H-benzoimidazole; 1-methyl-2-(2- diisopropylphosphinophenyl)-1H-benzoimidazole; methyldiphenylphosphine; 1- methyl-2-(2-diphenylphosphinophenyl)-1H-benzoimidazole; 1,2,3,4,5-pentaphenyl- 1¢-(di-tert-butylphosphino)ferrocene; phenylbis[4-(3,3,4,4,5,5,6,6,7,7,8,8,8- tridecafluorooctyl)phenyl]phosphine; phenyldi(o-tolyl)phosphine; phenylphosphine; 4,4¢-(phenylphosphinidene)bis(benzenesulfonic acid) dipotassium salt hydrate; tetrapropylphosphonium bromide; triallylphosphine; tribenzylphosphine;
tributylphosphine; tri-n-butylphosphine; tri-tert-butylphosphine; tri-tert- butylphosphine; tri-tert-butylphosphine; tributylphosphine tetrafluoroborate; tri-tert- butylphosphonium tetrafluoroborate; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine; tricyclohexylphosphine tetrafluoroborate;
tricyclopentylphosphine; tricyclopentylphosphine tetrafluoroborate; triethylphosphine; triethylphosphine; ((4-trifluoromethyl)phenyl)di-tert-butylphosphine, tri(2- furyl)phosphine; ((2,4,6-tri-isopropyl)phenyl)di-cyclohexylphosphine;
triisopropylphosphine; triisopropylphosphonium tetrafluoroborate; trimethylphosphine; trimethylphosphonium tetrafluoroborate; tri-1-naphthylphosphine; trioctylphosphine; triphenylphosphine; triphenylphosphine hydrobromide; 4- (triphenylphosphonio)butane-1-sulfonate; tripropylphosphine; tris[3,5- bis(trifluoromethyl)phenyl]phosphine; tris(4-chlorophenyl)phosphine;
tris(diethylamino)phosphine; tris(2,6-dimethoxyphenyl)phosphine;
tris(dimethylamino)phosphine; tris(3,5-dimethylphenyl)phosphine; tris(2,4-dimethyl-5- sulfanatophenyl)phosphine trisodium salt; tris[2-(diphenylphosphino)ethyl]phosphine; tris(4-fluorophenyl)phosphine; tris[4-(heptadecafluorooctyl)phenyl]phosphine;
tris(hydroxymethyl)phosphine; tris(4-methoxy-3,5-dimethylphenyl)phosphine; tris(o- methoxyphenyl)phosphine; tris(4-methoxyphenyl)phosphine; tris(4-methyl-1- piperazinyl)phosphine; tris(pentafluorophenyl)phosphine; tris(1- pyrrolidinyl)phosphine; tris[4-(tridecafluorohexyl)phenyl]phosphine; tris[4- (3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)phenyl]phosphine; tris(4- trifluoromethylphenyl)phosphine; tris(2,4,6-trimethoxyphenyl)phosphine; tris(2,4,6- trimethylphenyl)phosphine; tris(trimethylsilyl)phosphine; tri(o-tolyl)phosphine; tri(p- tolyl)phosphine; tri-o-tolylphosphine tetrafluoroborate; and 2- (dicyclohexylphosphino)-3,6-dimethoxy-2¢,4¢,6¢-triisopropyl-1,1¢-biphenyl or acceptable salts thereof.
12. The process according to claim 11, wherein the at least one phosphine compound is selected from the group consisting of triphenylphosphine, 1,3- bis(dicyclohexylphosphino)propane, 1,4-bis(diphenylphosphino)butane, di-tert- butyl(phenyl)phosphine and tri-tert-butylphosphine. 13. The process according to embodiment 1, wherein the at least one base is selected from the group consisting of organic bases and inorganic bases. 14. The process according to embodiment 13, wherein the organic bases are selected from the group consisting of N(R27)3, N-methyl piperidine, N-methyl pyrrolidine, N-methyl morpholine, piperidine, dimethyl amino pyridine, pyridine, lithium hexamethyldisilazide, sodium hexamethyldisilazide and tetra-C1-C6-alkyl ammonium hydroxide, wherein R27 is, identical or different, hydrogen, C1-C6-alkyl, C5-C14-aryl, or C3-C6-cycloalkyl. 15. The process according to embodiment 13, wherein the inorganic bases are selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide. 16. The process according to embodiment 15, wherein the alkali metal hydroxide is
selected from group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, rubidium hydroxide and cesium hydroxide;
wherein the alkaline earth hydroxide is selected from the group consisting of magnesium hydroxide, calcium hydroxide, strontium hydroxide and barium hydroxide; wherein the alkali metal bicarbonate is selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, rubidium bicarbonate and cesium bicarbonate;
wherein the alkaline earth bicarbonate is selected from the group consisting of magnesium bicarbonate, calcium bicarbonate, strontium bicarbonate and barium bicarbonate;
wherein the alkali metal carbonate is selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, rubidium carbonate and cesium carbonate;
wherein the alkaline earth carbonate is selected from group the consisting of magnesium carbonate, calcium carbonate, strontium carbonate and barium carbonate; wherein the alkali metal phosphate is selected from the group consisting of
monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate;
wherein the alkali metal alkoxide is selected from the group consisting of NaOR28, KOR28, RbOR28 and CsOR28; wherein the alkaline earth alkoxide is selected from the group consisting of Mg(OR28)2, Ca(OR28)2 and Ba(OR28)2; wherein R28 is, identical or different, C1-C4-alkyl. 17. The process according to embodiment 16, wherein the at least one inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate and tripotassium phosphate. 18. The process according to embodiments 13 to 17, wherein the at least one base is selected from the group consisting of potassium carbonate, 4-dimethylaminopyridine and triethylamine. 19. The process according to embodiment 1, wherein the process is performed in the presence of at least one solvent which is selected from the group consisting of esters, ethers, aromatic hydrocarbons and acetals. 20. The process according to embodiment 19, wherein the esters are selected from the group consisting of triethylorthoformate, trimethylorthoformate, tripropylorthoformate and tributylorthoformate. 21. The process according to embodiment 19, wherein the ethers are selected from the group consisting of tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, diethyl ether, diisopropyl ether, di-n-propyl ether, di-n-butyl ether, methyl-tert-butyl ether, diisobutyl ether and tetrahydropyran. 22. The process according to embodiment 19, wherein the acetals are selected from the group consisting of dimethoxymethane, dimethoxypropane and dimethoxybutane. 23. The process according to embodiment 19, wherein the aromatic hydrocarbons are selected from the group consisting of toluene, xylene, cyclohexane and monochlorobenzene. 24. The process according to embodiment 1, wherein the ratio of the at least one metal catalyst to the at least one compound of formula (III) is in the range of 1:100 moles to 1:500 moles. 25. The process according to embodiment 1, wherein the mole ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.075 to1:0.015. 26. The process according to embodiment 1, wherein the process is performed at a temperature in the range of 50 °C to 150 °C. 27. The process according to embodiment 1, wherein the process is performed at a pressure in the range of 5 bar to 20 bar. 28. The process according to embodiment 1, wherein the compound of the general formula (I) or its salts are isolated by at least one of the following steps: a) filtering the reaction mixture through celite bed to remove the catalyst and washing the bed with water,
b) concentrating the filtrate to remove the solvent and water,
c) diluting the concentrated mass with alcohol,
d) heating the reaction mixture of step c) to 60ºC and adjusting the pH to1.5 using 35% hydrochloric acid,
e) cooling the reaction mixture to 20ºC and separating the product by filtration, f) drying the product at 70 ºC -75 ºC under vacuum for 12 hours to isolate the compound of formula (I). EXAMPLES The characterization can be done by High Performance Liquid chromatography General Procedure: With due modification of the starting compounds, the compound of formula (I) can be prepared by procedures as given in below schemes. Example 1: Preparation of [3-(4,5-dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]- (5-hydroxy-1-methyl-pyrazol-4-yl)methanone. A round bottom flask (RBF) was charged with 22 gm (0.069 moles) of 3-(3-bromo-2-methyl- 6-methylsulfonyl-phenyl)-4,5-dihydroisoxazole followed by 100 gm of 1,4-dioxane and stirred it for 15 min. 17.6 gm (0.127 moles) of potassium carbonate was then charged in the round bottom flask. The reaction mixture was refluxed, and 50 gm of solvent was distilled off atmospherically. The slurry formed was then cooled to 25°C and transferred to clean pressure reactor, followed by addition of 6.8 gm (0.069 moles) of 2-methylpyrazol-3-ol, 2.07 gm (0.013 moles) of Sodium iodide, 0.72 gm (0.0027 moles) of Triphenylphosphine and 130 gm 1,4-dioxane. This reaction mixture was flushed with carbon monoxide gas, heated and stirred at 60°C for 30 min under carbon monoxide atmosphere. The reaction mixture was later cooled to 30°C. 0.88 gm (0.0003 moles) of Pd/C (RD-383) was added to the reaction mixture and the reaction mass was flushed with carbon monoxide gas and the reaction mixture was heated to 120°C under pressure of 15 bar of carbon monoxide gas for 20 hours. The reaction mass is then cooled to 60°C and the reactor was depressurized. 200 gm of water was added to the reaction mixture and was filtered through celite bed to remove catalyst and further the bed was washed with water. The filtrate was concentrated to remove 1,4-dioxane and water and the concentrated reaction mass was then diluted with 125 gm methanol. This reaction mixture was heated to 60°C and pH of reaction mixture was adjusted to 1.5 using 35% hydrochloric acid. The reaction mixture was then cooled to 20°C within 3- 4 hours and the product was separated by filtration. The filtered product was then dried at 70-75°C under vacuum for 12 hours. The isolated product (i.e. [3-(4,5-dihydroisoxazol-3-yl)- 2-methyl-4-methylsulfonyl-phenyl]-(5-hydroxy-1-methyl-pyrazol-4-yl)methanone) had a yield of 84.4% with purity of 99.37%. Example 2: Preparation of [3-(4,5-dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]- (5-hydroxy-1-methyl-pyrazol-4-yl)methanone A pressure reactor was charged with 22 gm (0.069 moles) of 3-(3-bromo-2-methyl-6- methylsulfonyl-phenyl)-4,5-dihydroisoxazole followed by 180 gm 1,4-dioxane, 17.6 gm (0.12 moles) of Potassium Carbonate, 0.72 gm (0.0027 moles) of triphenylphosphine and 6.8 gm (0.069 moles) of 2-methylpyrazol-3-ol. This reaction mixture was flushed with carbon monoxide gas then heated and stirred at 60°C for 30 min under carbon monoxide atmosphere. The reaction mixture was cooled to 30°C and 0.071 gm (0.0004 moles) Palladium Chloride catalyst was added to the reaction mixture and the reaction mass was flushed with carbon monoxide gas. The reaction mixture was heated to 120°C under pressure of 15 bar of carbon monoxide gas for 20 hours. The reaction mass was then cooled to 60°C followed by depressurizing the reactor. Further 200 gm of DM water was added to reaction mixture followed by 0.7 gm activated carbon and the reaction mixture was filtered through the celite bed to remove catalyst and the bed was washed with 100 gm water. The main filtrate and the washings were combined and were concentrated to remove 1,4-dioxane and water. The concentrated reaction mass was then diluted with 125 gm methanol and further the reaction mixture was heated to 60°C and the pH of reaction mixture was adjusted to 1.5 using 35% hydrochloric acid. The reaction mixture was then cooled to 20°C over a period of 3-4 hours and the product was separated by filtration. The filtered product was then dried at 70-75°C under vacuum for 12 hours. The isolated product ( i.e. [3-(4,5- dihydroisoxazol-3-yl)-2-methyl-4-methylsulfonyl-phenyl]-(5-hydroxy-1-methyl-pyrazol-4- yl)methanone) had a yield of 76% with a purity of 99.81%. Example 3 to 10 were performed as per examples 1, however the reaction conditions for the same are illustrated in table 2. The above examples do not restrict the invention in any manner.
Figure imgf000032_0001
.6 .8 .0 .0 .6 .4 .0 .9
Figure imgf000033_0001
Purity of the isolated product: at least 99%

Claims

Claims:
1. A process for the preparation of a compound of the general formula (I) or its salts,
Figure imgf000034_0001
wherein
R1 is C1-C4 alkyl, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl and R4 is C1-C4 alkyl, comprising at least the step of reacting a compound of formula (II),
Figure imgf000034_0002
wherein
R1 is C1-C4 alkyl and M is H or an alkali metal atom with a compound of formula (III),
Figure imgf000034_0003
wherein
X is Cl, Br, I, S(=0)2-CH3 or S(=0)2-CF3, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl, and R4 is C1-C4 alkyl, in the presence of carbon monoxide, at least one alkali metal iodide, at least one base, at least one metal catalyst and at least one phosphine compound.
2. The process according to claim1, wherein the compound of general formula (III) is obtained by one or more of the following steps: a) reacting a nitro-methylphenyl compound of formula IV,
Figure imgf000035_0001
(IV),
wherein R2 is Cl or C1-C4 alkyl, with an organic nitrile of the formula R5 -ONO, wherein R5 is n-butyl, in the presence of at least one base to give and oxime of the formula (V),
Figure imgf000035_0002
wherein R2 is Cl or C1-C4 alkyl, b) cyclization of the oxime of the formula (V) with an alkene of the formula (VI),
Figure imgf000035_0003
wherein R6, R7, R8 are, identical or different, hydrogen or C1-C4 alkyl, in the presence of at least one base to give a compound of formula (VII),
(VII),
wherein R2 is Cl or C1-C4 alkyl and R3 is hydrogen or C1-C4 alkyl, c) reducing the compound of formula (VII) in the presence of at least one catalyst to give the compound of formula (VIII),
Figure imgf000036_0001
(VIII),
wherein R2 is Cl or C1-C4 alkyl, and R3 is hydrogen or C1-C4 alkyl, d) substituting the para amino position in the compound of formula (VIII) to give the compound of formula (IX),
Figure imgf000036_0002
wherein R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1-C4 alkyl and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3; e) reacting the compound of formula (IX) with a dialkyl disulfide of formula (X) (X) wherein R4 is C1-C4 alkyl,
in the presence of an organic nitrile of the formula R5-ONO, wherein R5 is n-butyl, and at least one catalyst to give the compound of formula (XI),
Figure imgf000037_0001
wherein R2 is Cl or C 3
1-C4 alkyl, R is hydrogen or C1-C4 alkyl, R4 is C1-C4 alkyl, and X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3 f) oxidizing the compound of formula (XI) with at least one oxidizing agent to obtain the compound of formula (III),
Figure imgf000037_0002
(III),
wherein X is Cl, Br, I, S(=O)2-CH3 or S(=O)2-CF3, R2 is Cl or C1-C4 alkyl, R3 is hydrogen or C1- C4 alkyl, and R4 is C1-C4 alkyl,
3. The process according to claim 1 or 2, wherein R1, R2 and R4 are each methyl and R3 is hydrogen. 4. The process according to claim 1, wherein the alkali metal iodide is selected from the group consisting of sodium iodide, potassium iodide and lithium iodide. 5. The process according to claim 1, wherein the at least one metal catalyst is in a form of a free state of formula M or in a form of a metal complex of formula M(L)n,
wherein M is selected from the group consisting of nickel (Ni), cobalt (Co), iron (Fe), ruthenium (Ru), rhodium (Rh), palladium (Pd), iridium (Ir), platinum (Pt), silver (Ag), copper (Cu), zinc (Zn), molybdenum (Mo) and tungsten (W);
L is, identical or different, selected from the group consisting of Cl, Br, I, P(C5-C14- aryl)m, P(C5-C12-heteroaryl)m, P(C5-C12-heteroaryl)m(C5-C14-aryl)3-m, CN, C1-C6-alkyl, C1- C6-a I ky I -0-Ci-C6-a I ky I , -0-CO-C1-C6-alkyl, OH, nitro, -0-Ci-C6-a I kyl , C1-C4 haloalkoxy, C3-C8-cycloalkyl, C3-C8-halocycloalkyl, C3-C8-cycloalkenyl, C5-C14-aryl, C5-C14-aryl- (CH2)o-(Q)p-(CH2)o-C5-C14-aryl and 1,1’- bis(diphenyl phosphino)ferrocene ; whereby Q represents a bridging group selected from the group consisting of -CR9R10, -0-, -S-, - NR11R12, -Si R13R14 and -CO-, wherein R9 and R10, identical or different, are hydrogen, C1-C12 alkyl, C5-C14-aryl or C5-C12-heteroaryl; wherein R11, R12, R13 and R14, identical or different, are hydrogen or C1-C4 alkyl or R11 together with R12forms C5-C12-membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl or C5-C12-membered heteroaryl; and L is unsubstituted or further substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -N02; -NR10 R11, - P(phenyl)2, -OH, unsubstituted or substituted C1-C12-a I ky I , C2-C6-alkenyl, C2-C6- alkynyl, unsubstituted or substituted C5-C14-aryl, unsubstituted or substituted C5-C12- heteroaryl, C5-C12-membered heterocycloalkyl, C5-C14-membered heterocycloalkenyl, - 0-(CH2)r-0-, -C(=0)R15.-C(=0)-0-R16 , -C=N-R17, -S03H, -O-C1-C6-alkyl and -O-Si-C1- C4-a I ky I ; or
L is supported on silica gel, dendrimers, polystyrenes or mesoporous siliceous foam,
wherein
R15 is hydrogen or C4-C4-a I ky I ;
R16 is hydrogen or C4-C4-a I ky I ;
R17 is hydrogen, C1-C12-a I ky I , C2-C6-alkenyl, C2-C6-a I ky ny I , C5-C14-aryl, C5-C12-heteroaryl or C3-C12-cycloalkyl;
n is 0, 1, 2, 3,
4,
5 or 6;
m is 1,2 or 3;
o is 0,1 or 2
p is 0,1 or 2 and
r is 1,2, 3, 4 or 5,
or their acceptable salts thereof.
6. The process according to claim 5, wherein M is selected from the group consisting of nickel (Ni), iron (Fe), palladium (Pd) and copper (Cu).
7. The process according to claim 5, wherein Lis, identical or different, selected from the group consisting of Cl, Br, I, P(C5-C14-aryl)m, CN, unsubstituted or substituted C1-C12- alkyl, C1-C4 alkoxy, C3-C8-cycloalkenyl, -0-CO-C!-C6-alkyl, C5-C14-aryl, 1,1’- bis(diphenyl phosphino)ferrocene and C5-C14-aryl-(CH2)0-(Q)p-(CH2)0-C5-C14-aryl, whereby m, o, Q and p are as defined as in claim 7.
8. The process according to claim 1, wherein the at least one phosphine compound is of the formula RC4C2C3 or (RC1C2)2(B)F whereby X4, X2and X3, identical or different, are F, Cl, Br, I, -NR18R19. hydrogen, -O-C1-C6-alkyl, -O-CO-C1-C6-alkyl, C1-C12-alkyl, C2-C6- alkenyl, C2-C6-a I ky ny I , C5-C14-aryl, C5-C12-heteroaryl, C3-C12-cycloalkyl, C3-C12- cycloalkenyl, C3-C12-heterocycloalkyl, C3-C14-heterocycloalkenyl or -Si- (C1-C12-a I ky l)3, whereby B is CR20R21, -0-, -phenyl-O-phenyl-, -S-, -NR18R19, -Si R22R23 or -C(=0)-, wherein R20 and R21, identical or different, are hydrogen, C1-C12-a I ky I , C5-C14-aryl or C5- C12-heteroaryl, wherein R18, R19, R20 and R21, identical or different, are hydrogen or C4- C4-a I ky I or R18 together with R199forms C5-C12-membered heterocycloalkyl, C5-C14- membered heterocycloalkenyl or C5-C12-heteroaryl; whereby X4, X2and X3 , identical or different, are unsubstituted or substituted by 1, 2, 3, 4 or 5 identical or different groups selected from the group consisting of Cl; F; Br; I; CN; -N02; -NR18R19, - P(phenyl)2, -OH, unsubstituted or substituted C1-C12-a I ky I , C2-C6-alkenyl, C2-C6- a I ky ny I , unsubstituted or substituted C5-C14-aryl, unsubstituted or substituted C5-C12- heteroaryl, -0-(CH2)r-0-, -C(=0)R24 -C(=0)-0-R25. -C=N-R26, -S03H, -O-C1-C6-alkyl and -0-Si-C1-C4-a I ky I , C5-C12-membered heterocycloalkyl, C5-C14-membered
heterocycloalkenyl and C5-C12-heteroaryl;
wherein q is 1, 2, 3, 4, 5 or 6;
r is 1, 2 ,3, 4 or 5;
R24 is hydrogen or C4-C4-a I ky I ;
R25 is hydrogen or C4-C4-a I ky I ; and
R26 is hydrogen, C1-C12-a I ky I , C2-C6-alkenyl, C2-C6-a I ky ny I , C5-C14-aryl, C5-C12 heteroaryl or C3-C12-cycloalkyl;
or their acceptable salts thereof.
9. The process according to claim 1, wherein the at least one base is selected from the group consisting of organic bases and inorganic bases.
10. The process according to claim 9, wherein the organic bases are selected from the group consisting of N(R27)3, N-methyl piperidine, N-methyl pyrrolidine, N-methyl morpholine, piperidine, dimethyl amino pyridine, pyridine, lithium hexamethyldisilazide, sodium hexamethyldisilazide and tetra-Ci-C6-alkyl ammonium hydroxide, wherein R27 is, identical or different, hydrogen, Ci-C6-alkyl, C5-C14-aryl, or C3-C6-cycloalkyl.
11. The process according to claim 9, wherein the inorganic bases are selected from the group consisting of alkali metal hydroxide, alkaline earth hydroxide, alkali metal bicarbonate, alkaline earth bicarbonate, alkali metal carbonate, alkaline earth carbonate, alkali metal phosphate, alkali metal alkoxide and alkaline earth alkoxide.
12. The process according to claim 1, wherein the process is performed in the presence of at least one solvent which is selected from the group consisting of esters, ethers, aromatic hydrocarbons and acetals.
13. The process according to claim 1, wherein the ratio of the at least one metal catalyst to the at least one compound of formula (II I) is in the range of 1:100 to 1:500 moles.
14. The process according to claim 1, wherein the ratio of the at least phosphine compound to the at least one metal catalyst is in the range of 1:0.010 to 1:0.2.
15. The process according to claim 1, wherein the process is performed at a temperature in the range of 50 ° C to 150 ° C.
16. The process according to claim 1, wherein the process is performed at a pressure in the range of 5 bar to 20 bar.
17. The process according to claim 1, wherein the compound of the general formula (I) or its salts are isolated by at least one of the following steps: a) filtering the reaction mixture through celite bed to remove the catalyst and
washing the bed with water,
b) concentrating the filtrate to remove the solvent and water,
c) diluting the concentrated mass with alcohol,
d) heating the reaction mixture of step c) to 60°C and adjusting the pH tol.5 using
35% hydrochloric acid,
e) cooling the reaction mixture to 20°C and separating the product by filtration, f) drying the product at 70 °C -75 °C under vacuum for 12 hours to isolate the compound of formula (I).
PCT/EP2020/051465 2019-01-25 2020-01-22 Process for preparation of heteroarylketones WO2020152200A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19153707.5 2019-01-25
EP19153707 2019-01-25

Publications (1)

Publication Number Publication Date
WO2020152200A1 true WO2020152200A1 (en) 2020-07-30

Family

ID=65234498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/051465 WO2020152200A1 (en) 2019-01-25 2020-01-22 Process for preparation of heteroarylketones

Country Status (2)

Country Link
AR (1) AR117876A1 (en)
WO (1) WO2020152200A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125897A (en) * 2020-09-30 2020-12-25 江苏七洲绿色化工股份有限公司 Preparation method of topramezone
CN114057715A (en) * 2021-11-22 2022-02-18 安徽宁亿泰科技有限公司 Preparation method of topramezone
CN114163428A (en) * 2022-02-11 2022-03-11 江苏七洲绿色科技研究院有限公司 Preparation method of topramezone
CN115322185A (en) * 2022-10-14 2022-11-11 潍坊新绿化工有限公司 Preparation method of topramezone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026206A1 (en) 1995-02-24 1996-08-29 Basf Aktiengesellschaft Pyrazol-4-yl-benzoyl derivatives and their use as herbicides
WO1998031681A1 (en) 1997-01-17 1998-07-23 Basf Aktiengesellschaft 3-heterocyclyl-substituted benzoyl derivatives
WO1999058509A1 (en) 1998-05-11 1999-11-18 Basf Aktiengesellschaft Method for producing isoxazoline-3-yl-acyl benzene
WO2009007329A1 (en) * 2007-07-06 2009-01-15 Basf Se Crystalline form of [3-(4,5-dihydro-3-isoxazolyl)-2-methyl-4-(methylsulfonyl)phenyl]-(5-hydroxy-1-methyl-1h-pyrazol-4-yl)methanone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026206A1 (en) 1995-02-24 1996-08-29 Basf Aktiengesellschaft Pyrazol-4-yl-benzoyl derivatives and their use as herbicides
WO1998031681A1 (en) 1997-01-17 1998-07-23 Basf Aktiengesellschaft 3-heterocyclyl-substituted benzoyl derivatives
WO1999058509A1 (en) 1998-05-11 1999-11-18 Basf Aktiengesellschaft Method for producing isoxazoline-3-yl-acyl benzene
WO2009007329A1 (en) * 2007-07-06 2009-01-15 Basf Se Crystalline form of [3-(4,5-dihydro-3-isoxazolyl)-2-methyl-4-(methylsulfonyl)phenyl]-(5-hydroxy-1-methyl-1h-pyrazol-4-yl)methanone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIVEK, TETRAHEDRON, vol. 63, 2007, pages 6949 - 6976

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125897A (en) * 2020-09-30 2020-12-25 江苏七洲绿色化工股份有限公司 Preparation method of topramezone
CN114057715A (en) * 2021-11-22 2022-02-18 安徽宁亿泰科技有限公司 Preparation method of topramezone
CN114163428A (en) * 2022-02-11 2022-03-11 江苏七洲绿色科技研究院有限公司 Preparation method of topramezone
CN114163428B (en) * 2022-02-11 2022-06-10 江苏七洲绿色科技研究院有限公司 Preparation method of topramezone
CN115322185A (en) * 2022-10-14 2022-11-11 潍坊新绿化工有限公司 Preparation method of topramezone
CN115322185B (en) * 2022-10-14 2023-01-31 潍坊新绿化工有限公司 Preparation method of topramezone

Also Published As

Publication number Publication date
AR117876A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
WO2020152200A1 (en) Process for preparation of heteroarylketones
CA2610776C (en) Process for production of mono-substituted alkylated compound using aldimine or derivative thereof
WO2011056737A1 (en) Novel chiral phosphorus ligands
CN106187808A (en) The preparation method of AHU-377, AHU-377 intermediate and the preparation method of AHU-377 intermediate
KR20110036055A (en) Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
EP3019509A1 (en) Novel chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
JP5583009B2 (en) Process for palladium-catalyzed coupling of terminal alkynes and aryl tosylates
JP2008505903A (en) Formation of tetrasubstituted enamides and this stereoselective reduction.
JP2020537679A (en) Process for producing herbicidal pyridadinone compounds
JP2004509947A (en) Lactam-substituted propanoic acid derivatives with high enantiomeric purity and methods for their preparation and use
WO2019016115A1 (en) Process for the preparation of substituted aryl ketones
KR20070107802A (en) Method for obtaining a pharmaceutically active compound(irbesartan) and its synthesis intermediate
US20050107608A1 (en) Ligands for use in catalytic processes
JP7373241B2 (en) Method for producing pyrimidinyl bipyridine compounds and intermediates therefor
JP7167171B2 (en) Method for producing tetracyclic compound
CN112300214B (en) Palladium complex, preparation method thereof and preparation method of axial chiral biaromatic compound
TW201730151A (en) Processes to produce brivaracetam
TW201522282A (en) Monoarylation of aromatic amines
CN106432330B (en) The midbody compound and its preparation method and application of LB80380 drug
RU2793738C2 (en) Method for preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides
TWI796463B (en) Process for preparing 2,6-dialkylphenylacetic acids
CN111417618B (en) Process for preparing enantiomerically and diastereomerically enriched cyclobutane amines and amides
CN113861237B (en) Organophosphorus ligand, preparation method and application thereof
TW202342438A (en) Processes for the preparation of n-(1-methylcyclopropyl)-2-(3-pyridinyl)-2h-indazole-4-carboxamide and intermediates thereof
JP4509327B2 (en) Process for producing N, N-disubstituted-4-aminocrotonic acid ester

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20701958

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20701958

Country of ref document: EP

Kind code of ref document: A1